var title_f8_48_8960="TPO physiology";
var content_f8_48_8960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Thrombopoietin physiology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 209px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mechanism by which thrombopoietin (TPO) regulates platelet production from megakaryocytes. TPO (size of large arrows indicates relative concentration) is produced at a constant rate by the liver and enters the circulation. Left side: When the platelet count is normal, high affinity TPO receptors on the platelets clear most of the TPO and produce a normal plasma TPO concentration, thereby providing basal stimulation of bone marrow megakaryocytes and a normal rate of platelet production. Right side: When platelet production and the platelet count are low, the overall clearance of TPO is reduced, sequentially increasing the plasma TPO concentration and megakaryocyte and platelet production.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Kuter, MD, DPhil.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8960=[""].join("\n");
var outline_f8_48_8960=null;
var title_f8_48_8961="Thyroglossal duct remnant";
var content_f8_48_8961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Position of thyroglossal duct remnants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 497px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the position of thyroglossal duct remnants: (1) intralingual - 2 percent, (2) suprahyoid - 24 percent, (3) thyrohyoid - 61 percent, (4) suprasternal - 13 percent.",
"    <div class=\"footnotes\">",
"     Note: percentages taken from Allard RH, Head Neck Surg 1982; 5:134.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8961=[""].join("\n");
var outline_f8_48_8961=null;
var title_f8_48_8962="Patient information: Acute abdomen (belly pain) (The Basics)";
var content_f8_48_8962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16925\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\">",
"         Organs inside the abdomen (belly)",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"          Anatomy of the urinary tract",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"           Female reproductive anatomy",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36129\">",
"         Patient information: Appendicitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/20/35138\">",
"         Patient information: Ectopic pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/8/5251\">",
"         Patient information: Endometriosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/56/43905\">",
"         Patient information: Kidney stones in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/39/6770\">",
"         Patient information: Small bowel obstruction (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/24/25986\">",
"         Patient information: Stomach ache and stomach upset (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Acute abdomen (belly pain) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/acute-abdomen-belly-pain-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H8006038\">",
"      <span class=\"h1\">",
"       What is an acute abdomen?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors use the term &ldquo;acute abdomen&rdquo; to describe an episode of belly pain that starts suddenly and lasts for a few hours or longer. Doctors use the word &ldquo;acute&rdquo; when something starts suddenly. The &ldquo;abdomen,&rdquo; or belly, is the part of the body between the chest and the genital area.",
"     </p>",
"     <p>",
"      When people have an acute abdomen, their pain is so severe that it makes them want to go to the hospital or see their doctor or nurse right away.",
"     </p>",
"     <p>",
"      The pain symptoms are different for different people. The pain can feel sharp or crampy. People can feel the pain all over their belly, or only in 1 part. Some people feel better if they curl into a ball, while others need to lie flat and completely still.",
"     </p>",
"     <p>",
"      An acute abdomen can happen in both adults and children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8006055\">",
"      <span class=\"h1\">",
"       What causes an acute abdomen?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An acute abdomen can have different causes. Most of the time, an acute abdomen happens when there&rsquo;s a serious problem with 1 or more organs in the abdomen. Organs in the abdomen include the digestive, urinary, and female reproductive systems (",
"      <a class=\"graphic graphic_figure graphicRef64960 \" href=\"UTD.htm?39/54/40804\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 3",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Conditions that affect the chest or genital area can also cause an acute abdomen. Even though these organs aren&rsquo;t in the belly, people might still have pain in their belly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8006070\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. People with an acute abdomen should see their doctor or nurse or go to the hospital right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8006085\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. The doctor or nurse will ask about your symptoms, including where your pain is and what it feels like. He or she will ask about your current and past medical conditions, and do an exam. Your doctor might do repeat exams over time to follow your symptoms.",
"     </p>",
"     <p>",
"      Your doctor will decide which tests you should have based on your symptoms and individual situation. The tests might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        X-rays",
"       </li>",
"       <li>",
"        An ultrasound, CT scan, or other imaging test &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8006100\">",
"      <span class=\"h1\">",
"       How is an acute abdomen treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on what&rsquo;s causing the pain. It might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fluids given by IV",
"       </li>",
"       <li>",
"        Pain medicines",
"       </li>",
"       <li>",
"        Antibiotic medicines to treat an infection",
"       </li>",
"       <li>",
"        Other medicines to treat other medical conditions",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most conditions causing acute abdominal pain do not need surgery. But some conditions are life-threatening and need to be treated right away with surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8006115\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=see_link\">",
"       Patient information: Stomach ache and stomach upset (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36129?source=see_link\">",
"       Patient information: Appendicitis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/39/6770?source=see_link\">",
"       Patient information: Small bowel obstruction (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/56/43905?source=see_link\">",
"       Patient information: Kidney stones in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=see_link\">",
"       Patient information: Ectopic pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=see_link\">",
"       Patient information: Endometriosis (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/48/8962?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16925 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.78.124.10-D68EE5DB58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8962=[""].join("\n");
var outline_f8_48_8962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8006038\">",
"      What is an acute abdomen?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8006055\">",
"      What causes an acute abdomen?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8006070\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8006085\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8006100\">",
"      How is an acute abdomen treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8006115\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16925\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\">",
"      Organs inside the abdomen (belly)",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"       Anatomy of the urinary tract",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"        Female reproductive anatomy",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36129?source=related_link\">",
"      Patient information: Appendicitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=related_link\">",
"      Patient information: Ectopic pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=related_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/56/43905?source=related_link\">",
"      Patient information: Kidney stones in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/39/6770?source=related_link\">",
"      Patient information: Small bowel obstruction (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=related_link\">",
"      Patient information: Stomach ache and stomach upset (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_48_8963="Keloid injection";
var content_f8_48_8963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralesional injection at the edge of a keloid on the chest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The slightly hypopigmented scar just below the injection site is a successfully treated keloid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Mosby, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8963=[""].join("\n");
var outline_f8_48_8963=null;
var title_f8_48_8964="Acne conglobata";
var content_f8_48_8964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acne conglobata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5YkdvMb5j1Pem72/vN+dEn+sb6mm0AO3t/eb86N7f3m/Om0UAO3t/eb86N7f3m/Om0UAO3t/eb86N7f3m/Om0UAO3t/eb86N7f3m/Om0UAO3t/eb86N7f3m/Om0UAO3t/eb86N7f3m/Om0UAO3t/eb86N7f3m/Om0UAO3t/eb86N7f3m/Om0UAO3t/eb86N7f3m/Om0UAO3t/eb86N7f3m/Om0UAO3t/eb86N7f3m/Om0UAO3t/eb86N7f3m/Om0UAO3t/eb860NHjjuLvbcmRowMkKcfme1Ztdb4J0qa5vkcZjYEHLLn5e/ynr2rGvNQg3c1owc5pJHpXhe2hS0DQSSKgwcNwxP1/p3/AArsLWMKqqrTDoGDKQSP6f59Ky9H05Yi5ztIxtyN/PqB3rrLe2XIO7zCpJzuJOB7d+a+bnJts+lprkVjOea8W6YqZI4EHUDnPXpVO+GEZFmlw43FiOn0XtWzIVUt5e5mBB6kgnv16/SqJs5EDM0yujEkll+7249qcb3O6nJJ9irZiF1AWQsg+bLqOnfH41Z85HZgJCRGB8ypyP8AHrVKZ0iQIssJUHGB0bjse9V4md5E55Izk8D/AD7VTRt7O+prMZAdk0gVduQSu4H8f6075Yp2aOZ9pPQ9T/n1p1raCRVaVwpAOFzyR9PX2oaa3aVFhIChQHJHbnn61cVbcI+Rm/bZFncu0iowO0EdOe3+NaKlpnD7pNxPUD29O9Pmgs44JJC4mi2Yi6kK2emfbrim25ghGYZgdx6Yyc46+30rVwT1CTUldIUxKFcku8rICu1eM554+lVZBKxLKX6HC9dxq4knmZCuquqANn+eapzxKrshcZUEAbiMn0z+tYImK11IIm8xNzLJu77Yt/PufWipbVgIh5xRX9329vaimoXRo4yvoj5bk/1jfU02nSf6xvqabX0p+fhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFKOtXtL0q91S48mytpJW4ztUkKPU16f4Z+HEdpMsupTLLJlcKFyoHf6+lYVsRCktXqdFHDTrPRaHHeGfCNzqL+bcoVh25AHUH1PtXs2gaBDYQYUglQABjlsjuew9K2NJ0+BLWSONCRjGwR4C++fatSTTRLHlLgoAeQExk14tetOtq9j3MPhYUlbqFvaM6yBQpBAOd3BHrn+tGpTww+c80j2yKfmyeT7fStO5lFvCoaaPKfISv8AMf4VlarBb3O9pWwx5IkXavTpz371mopbnVRV2m9ivbN51vJOs4APAcyDH+9/SnNdwC1YHfNKq5IzgE/1FQ2FvZQRMVZZ4GGTheFHqBVSCaK8SRGJhXHGU4YD0J6YqbWZ08qbu+hRsra6up/OmRUjb5guMnHsKlkvNku0bEhyDnOCfetu2dI7aJYxkjqAMkD6+9Zio1w3m4gJU5Afp+YovY1hNyu5ISFZVuZTLJhACSw5/wCA/X9afculkpdR5jYGS3THr+NV/wC02bzBO9tE2eYNw3ufYdSe9Z8lyb65BZndZD0C4XHantqzaMW375fbWVeMtPbjyz0UNgMec8CpTcQtIGjjDOD0iPH4/hVK3sES3RzGWKk/K3RPaoZpHe8jgtJYYFLnJYfIOOhPXnpWiqN6Icox1tsbEUibupVQuQ6imS6oUQxGEzKDjLL09cVnSXXlxIJIz547IchV7ceme9VRbXE0gnt7sN1DQuAApHJ59cVMfMXIt5I2kkaYFraQRxDhVCA0VSgh2RjzJGQn5gApbI9eDRVK7Rp6HzVJ/rG+pptOk/1jfU02voj85CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKlghlnkWOCN5HY4VUUkk+lGwEVFdLp3hDULkb50MMQxuz94fhXbaN4S0u0uI4zA01w5AVpvuDnqT29xXNUxUIbandRy+tV1tZeZ5zpehX+pPH9nt3KOcB8cV6F4a+HKJBDd6jcW7ksG2q5JXB6Y6fX0r0aztY9MWMSrBJcBSMRDCjPTFSQalO/JgZIs4XMYCse+D2Pt3rhq4qc9Nj1qGVwhaUtfX/IZpeli3jiSC227pMKSNm72yK6IqLZVgukTzC4wiNuHpnNZ1vewXVuY5DHDIjbTJM+0KfQfhzTJtU07yEWC+S6eLK5UDJPr71y26nb7FuyaNF5ZI7qVZokQkbVBbGPYjvUcl1ZxrJI9yoY/Ls34IBB6/0rMlZlg330zKJDwB0I54z61nLcWykRxQ5LHDAnduz/AC+tZN3NPZ6XQtz4js57qaO2keTbtUs/8OfQDrSx3l4IyAUSJyUAlbcR64B5PrUV2ljFJIpv7K2mZMtkqCMVk6ubEq8smpwNtG12VsEA+gHrT0exrHY2/NaCQt9pjuYnGVkjY7R2qG5vrt8GFAyIvrkY+uK5i1jE4DXV15lsACsfKDbnuBVt9Wshem0geVY2TCuBgdemKfLroXG2jloTLqWs3bzpc2kKQu4ACSYYDHc/4VrXFy0ceTwqpnELYz2yQe/tVMXkcVrLJYsbiSL5RsXJfj3p0UzW9qks9r+9Zcko27J7nnoKmT10RpGGqV9Say062n2mWfAI+8w4z/dz+taQOn2JJZ4jvbk7s8/TtWRp9280sao0cqEZKg9P8+tbfmxXkmy6gCSqm0EKPm98+tQ5a6jcX11Q2ciQOY1I3L8pJxyDzxVd9Nn8xPOiVmPZWyGH1FADKqhvMbC+Wm0dQOSD/jVrzruO3TNuy2u3hgpB/wDr1SaNE2lYzp1nZ3dLfgnAAPKjPBz/AEqpKWSXYiGLs/Xr6c9K0LfZA7Mkkiu/OG9PTHY08iJ5TGFKO3Rn5x9amOjLejM4XaIAPOf/AL625/CirsJMCYjAcN82RGH5PviitU1YtKXRHzXJ/rG+pptOk/1jfU02vpD8zCiiigAooooAKKKKACiiigAooooAKKKKACirVnY3N64W2heQk4yBwPxrc03wbqd9MERUHOD83Q+n1qJVYQ+JmtOhUqfDG5zNWLe1lnxsX5SQC5+6M+pr17Q/hxZQGKe6kglO3lXk4VgM4PuTXQwaRapGStnGYVcFUVdxz1zn2rjnjor4UejRyqctZux5j4d+H97qUxaZX+zxjc7RjOR9e1elaT4Ks7KONrZ1jkjUsBnLH0JPrW1o15sluEt41UsfmjX+EZ4/Or/nBELvhWG8ho1BbHPY/lXn1cRUqP3merQwUKLdlqYg0t5o97qBkhS2f6UyKzYErHEIySAE53E54P8AjVy0lL2wuI0nhw21HfAOR1/+tU9rPsMpaVS4BJZ3xznjn168Vk3oehd7xKy2dvZ25SFybpxtkJyxbPXA9qghnjMUBhkkeIsMkjGWBwce3rU16UlZYjKGMjckHH69c81GTFiCKVAYoyFjQtgD0Bx3NFyk2tCpfSx6ndNDKY4kZ9okzgjPr/jQINP0K+8yaKN51AkTacqPX2+vFQ3csNxI8UcLu+cgY2gYOM59qmkmcFmkCzspCuqnnp/hT5tCZK7t0M3UdTuLgmKG3acyHMZA+UE9x64qezjigshMZGecSMjxhMAKecjHU5+lXbGW1S3kuL0mMHhAhGdvbPpzVdtSRzL9iRiuQXUqBSctNhe9J3vscMLGzvfENxEbe4Z85LZOQRXXaLpGmWUirFpyiIZw8r7y7dcDNSzWhDzSDmU4+bGBj0OO1PzA0rxvG25/lwTgFff0+tVOo5K19CKWFV3OSNCKO3ySbNUjC5UJyG+mao3yWd6jbrKJVVfvAMNvvn19qRtOvftpQusyhvlEL5K4x17AYroLvTTHawtaMvlSDc4ccp2596y2eh03grJ9StoxfT4RNa/Zoon+SRpF3bR6qPrVVpHJnkbUo5geFRYx+P4+1SOILuQWyzM6g4AXhsYp8FlaW0pd1JSP5nB43H0+lKT0t1NFFRf9fIx9Q1QWpSJba6/eDiQRgsPcjpXLW2ralo2oNBdRmQhy5n3Z3gjgEHjPtXfzQ2ckismYY2+XYCTgdeM1bt9DimDMixyRnJI2jB47Z7VUakY6NEVb6SUrf11Oe0PxE9/Fj5ox93dIBk478VpmwvXuvMN+mI2wGVyVwOeKi+z29hLD5VoH8pCoUqFx1GcDrj3q9HcLdxgNG2zdgcgfWqk1F3iaxU1FXZIxa2IleYMWBbzGGRz7+tZvmRsGAAyT/rCcVfu4rxNoMxSFwdvAziqYltRZJAgkE+85YAEL2xWV7o1g9LsuW+m3gQmGUurHdwOh9OKKrW97c2itCssoKt82wAjP4iiritNzNwqt6WPnGT/WN9TTadJ/rG+pptfTH5wFFFFABRRRQAUUUUAFFFFABUsUEswYxRs4XG4gZxk4Fa2jeHrrUZLfAEcUrld7nA4Gfzr1fRPD2lWCfZbcBySGdmb7y54P4ntXLWxUaei1Z34bATrLmeiPJtI8Oanq1wkNnbMzMxTJGACOT+VegeGfhiWljfUnVh3xkrntj1zXpNhDBZuhhFt04ZWIXrypP9a1bvVorSN4IFghYkEZfO3J6D61wVMZUns7I9Wll1Om9rvzOf07w5ZRTix8pUjWTDhPlYgdMfiKnWygfUFwREnmBFBUFlH06cdaamoSzXzzLsVQ5bPcnpWZJqcsmry2kIzIv3i2Aq47e/1rkbbPSattpoaepGPTzI8bq8cRCrKB9/nG78ay9Okur37TdTSGK0QkbSMM2M9R2A7U3UG/0WQalcILcYbapOSPT/H+tVWvrMyrBCzRLMpIOMk7BnGM01boXfp/TJZdRkglijtArI7gMwHJz3roEs7C5mQ6hc/Z7cIz7ZXK+a3YAD3rFWe4u54IgqhRHuGBgLxkk/WptPSGOZpnhWaU5bzJWPuOnqKm66id5LT8DS1Rp7mwT7FapDawtsDnjP8Ae4/DisGzaS9uXH2cxBCVijYnMg6Bsds0ajevNL5E0juMg+XEMKAOQM96taZAFijCR+RvyT5jfMQT1NTtEpKSVkWZPKs7KFDKpu1b5URPuDuS3r0x/Sqz3xWLaiJsIILkY/X+dXp7KGYR7RI6wHzGIPBI6Z/pVO4tmuokLmMw+YFPU8E84/r6UXRrGPcz9Ov11CNsxyQwklRkcHsffrWrOY7aPBj8x1wuGG0+uBTxEkMjQwRsWGDhj09DUUkUiQhcgssgyyfMD+dJtX0K5LLVmZEY9R+ZQESPJ/fHCgf1qayntm/0exmWWTH7xYlyVx6fpVu8t4ntBBcKWEmSccfhgfrVSxsNPj33FsjRlgE8uLr9MUc6tqOzeq1L/mqY1lt3WSYkrtK4OezGrVtOZi+IN0ajauFAbd6ZqpPaCaPCqFDjau48Ad8+taFtZNbMXdUk2YDRknn6+9TzITsld7hdxSTQ+XHPFFGuGAUY3H0qO00yOV41+2XGCmNnQK2eBjPPFTfZ2jDMxRoz0IcsMVegvoxGEO0nByXH8iOvvVKTT1CXNFWgZ/8AZ9nHcKwLYU/KVHJOOaJbkPHLEiK6N2Izu46mr0eoSTj7Ox2245Eh9fb3qFHk+1rHA0LJKNo2g4C9e/0pSejErrWSMu0RLh7dp1O5eWUDIB6D8a2bedrFZZbdt0QUbyV75p9ukkc0ht0YOoJJPHzfQd/aop/3k81xKyEhh5i/dX8v6Vkm+oStJ2a/q5C90lzw1tG6oGYyNwT6Co4JY9uWgMcbcqGUAHjtViGMyM72g2RY24Ukkn0/DvU1zJKFiEi7UjBHmbsljgjitN9WUtHy2MWeKe8KiM5QDap7KByOf0qrcK7R7JRtdjyhGCCK0nlkhhhAmDts3PtOCvJ4qnqWorGYopwUXd5hI5ODzzThrodMW+2gts8Kx4lyrg87lBz70VHBbT3++aNgF3Yzjr70Vor22E6tOLsz5yk/1jfU02nSf6xvqabX0p+ahRRRQAUUUUAFFFSJGXDEEAKM5NA0rjAM8DrW/wCGtGa9ljnnXNuH243Bcn8areH9KutSuGFvH8ig75SDhB/jXTQaHIYY4nDRW5T72eX+vpXLXrKPup6nXhsO5+81oblnqdvC0CxTxh/L8sqmNkQBJIU45P1o1PW0t5ILaxiyNxdnJyXzwF46n19KrL4fCXOIWjwqhCXHzNyfTitGz0WezMa2sCJKCTJcEZdQRznPArzW4Xue7D2u2xJc6xdWKiJbZ/OYb3IbhT/dx7en1qLTNQv9kss8aTSOC8YXJEYz94+3atePTrSCFpRbp5wzmWY5Y88HHao7k6ldi2STyvJII2xcYXryfSs+ZHRFTdm2U5bu+uIWeW5gi2BmVYny3pkj1rJ0qz1y9meW3mNpaZCPMRkufaurGiRQ28lxqDi3tMAkbcE+/wBBUlnHanSi2lyi7RmxGWzlAfbgd6IzstAVKU5LmbMufS1a1S51I3htYGIV5MIJ26HH6fnViCWGBkllQrO/+qjUBiqj196nj8PzTXSGe6e5VMkROeFIHPHuOPw7U/VNKt5oo2k2xKDjC5JYdh7AUr33ZtGi76IYdVe4T7Iy4jLFtxAyM9KmigvEmEks0su8Yww5wP5HFWtH0izto5ZgGQSLuQYLKxHUHuM1qP5zSKMrvkAAUemP5VEnbRG3JYzRp874YJKbdskM4Hyr747VLH9rRmDRb4Y+mF6jvz2rQUX1t5eGYFn4Q8gD2rREygxpMQyZIbaDuOKnm0ErrTcxZ/OmhVX8xgGG4r0x2BP8qqz3FwsrvaNIowApwMHH/wBetqSSOG8hZSuXbChcnA9P8/rUIi8sK6lUJLEngjbnkCp5mWn5f1/SMZ5biCWFpmdk5PP3iT7UR3mQWuBKnz4G0DLehxWk1vEsoWcb+7bs/hTpLFWniCIjbvunkKfpRzGqfRlBlQ4ZpuSOc/w+59K0FWK3g3WxTchXdt6nimzIgtFIgAJ4wRwuOp+tNiims4YSwZgM8KuST2P1qHdob1SGS3EkhbepbgjOMBR71qadJ5U6wee+yTkq4xu9jTBJbTSKbSVRt5ZQDuP07cU0qoVJooQZGOCP4iaNjNq8eWxHqG8qQbWJLkvt82EkFh2JHT2oLG1trktPIzHCBCuD2zkelTTyBswrH83BxHnqe/PegSZlaCML1A4ztB9Oec5qnJtlxTstCFbnyzCnlOmPv5AO7jrRHcpGcgzdPlKqMDn9RU98BJK4lgXy/u8k4B/nTIYLfyXEW0gdMgj07fnU3a0FolsXRIZElV5JgzDORjp3+oqk8OyUoHd4i+fMOCu3tzT54YkWdZNjeWNqxjPfv9aSSAW8ZAR0j4Lbu+fWqknb/giStt1IZZZgrC0kYuy7mCnpz0/CqZlmkkYSsA5bI3Egc9/61Yt1R1OxBGka4O0HJOeQfwp7TQvbLIxUsoZB6ewppPZl2s9ilNGouzslFwu394yjgHJ5FVF0xZ5ZvsqPsUFmL88etTweYUVwigk8IRwfTNbqMbmKG1nJXIf5UGCeOM8dMgGtIRuy5uULWMGGC48sbEdl7HaTxRW7batcwQrGZEJUAckjoMdu1FCqru/6+YnVrrRRX3nypJ/rG+pptOk/1jfU02vpD84CiiigApQCSAOSaVVLsFUEsegFejeBvCTBJL6/iQ7ADtf+DJ/9C6VlVqxpK7N6FCVeXLE5+LwzLZwRS6hsW4m/1Ftn5m6fhWpF4bvL64mja12RRSCPyQdpY44Ar0SXQ7Q62t5diOSSAYBxld/YkH2ra8L6RYraNeXsLCWdvMRnzke3HGe9ebPEyevU9yGCjTVrafmY0HhiOysorcKsZjX7sTHAbvjPP51bTSg2qWloySS3UjZx0UYHX8q3dSlt4F2w75gORuALFq0dGQArKYle+cFAxHI/+tXLduVjt5PZw0RmQ6ZaW6QlbXyXUssZLZJwM5Hv657VU+bU5YbeLMbNvYTHHJ56CuptrY+bvvJFjRY2GFHzKDnv71Sto0trmM2tuHXnfIw+XGeuPT0pJf19xcLJStv/AMOZH/CNSWf2QOpIbJ3TY+Ruvb/PWpJNPhtukaNPPwwXpuz2rofEF1HHpyrEI57lfnQkHgZ7iueW4Etur3G4qzMTMfp+dNx7mtGMpJSZR1Kwtrm0a1aSWa7RyHjXsB3Jog0GOPS47mGYoISgVE754rorHSv+JYstvsUEll3DJfjk1UtZIrpEt4wyKuMSY/ipp6KxtFqV+V7bmWYZki3RqCxk8sqT827g1ft4jIHeRAUB2gnqHHb6itLbCVS3WJmR3Ikbb16cio4XMDSIYWEW5o7YBe/Q59am3X0DmctLEAXz2tfOXfLgjcT0HYDFWtNs44L65eZNzlTjJ5Xg1a06ylIxKxiihj3FQoO48nNQzyBdQUGMLbyEBZCMA5HJx1os3qzKUr80UNSycu5kmHmKVIdT068VUvWlt42RFXY27r1H19z/AJxWpMFQOFbeUcBWYfyx/Wq2qeWmmLLMVXccoCP5elYtt6IVNtyXW5m2sMkiyy7GnhXAPmcAEip44opBDNe71lU8IxwvB46Ul5dqtnGYV8uLcuXxgZA5xVRZo1ePZNG6HOUOSPp+NS7myhKSuWbjM5EpVlLOcrkZIFRmVWl3IWVcglhzggcZ9qls5IzaeYZAWJIUAcgdz+FQRzm2sCqxZYPtKsBtz/MZoVxpdBFhN7J5ERKtGu8H2zkj6HNEksnmMGuWWUEKGPIx3NQ2GZfMLq6SbCFCfdJP+TV0RQRX6Q3ATBw27GcgDkj0Ip3t/wAOaP3W1vYls5UE88CupjBVvMPt9O1Jf2181m9xbOGtkYkJ1wB/F64qvL5Vw6jygjtlV2jHXpn0471DCLq1mk+zz+Wy5YhBnt1qlbqChrdb+f8AX4ive+XbpcvEiB1G1c5L89/1qxZrIJ0llfzV8skAtg4+tQ3UEZhM14I47ogbUVTwfUDtTYIUjjEc5EjMvGFxtFS7rRCaTj7pbknNwHEI37cbS3G7saZaM24JuWBGUK+D0Oajs7uS1MkcQAEhIViOPcVBp12b2IgiJbm1OCpXl+eMevWk7icGl5GwsFstoz2+xZRncCcnb7D3OKo3d+8i7pnIuVXaY8YVfcetTQ3FtHGrOZfNl5kyoIP0pLi9jlgi84J5y4iG5eo7/jVK1rIiKaeqv/X9fgVbPTxPbAxyYuCMhT/Ef8MVHe2IiZRevAJN/GH6ZHUcdKsWtyP9ISDLBHZy/AYdAB9Kgu5YJnDyQlZmTErMoxkHr9a1SirqW5rGc+Zp7DwsUKNG3yXSfM3Ocjtj2NUru+zG0UUjxkMXTJ/zzTLdSt4ZpwH86NYmPooORmrk9sk2ZYoswp8u7HUfSlz2ty7GsbJ+8RRXU0kSERkkKFJ3YyQOtFTRQ3KxqIbWORcDmVMke2fSioU01qLlXS33ny7J/rG+pptOk/1jfU02vpz84Ciirel2Uuo6hBawKWeVwoApNpK7Gk27I7T4b+G21CQXU0SvFvAAzhv/ANR5969l0fTVht7oOiboj8u2Tqwx/wDqqtoWlJpWlTBWIaTGw4HygKBWxGEsoli8tQ8gGHGAXOO3r+NeNWnzy5mfUYWiqUFFFR5hcPN5kcazs2WdRwvTnn+VdEgzaYhYM0eY0TdjAx2z0H1rjrKGWG7ui6pM7L5e1gSNuRz9Af1rp44dyq7qd8iASM4zg+n19awi9djrqQUWmmZlposUdktwpWWbjcpY4Vc8Y/GtvWHj+2WMcEABV8OpON3HOPYetTNJHbaTLMscSLEoJCrxu4wfp6Vk3epM8bo0cf2oqCrFcgg9cH0pNJErmm+Zvv8A18jUCJd6lthlLoq7Tlu/oPRsd6i1WRFaOCESRplgrlhhxgjI/lWdJOsKrHbCVX6OU5+bHJz3yKpxgySRfMsojBCxrxgc8j2z2qubS9v60NIUtVK4/UYmzAiMrOm1C5PK9cge9V7sxeXEIArzK5ByeMf41JFIBePHerI7CQ7QoBII/wA81AgS61FzbxMFIEmzGck9cVG+h2JW36F7RprgSErKqsi/6o5IwOv4VcWOKK3jkmCPFIchicE/hVC3VY7qRV3CXbtxxggZ3Z960GsXexhlmix5MZWMgcLnHzH0q4qy/ryMajSnfa9hmnxRyOhWVWWR2O4EjBGMEj1rZVYomtmVIxKr4XcSRn1H9P1qK1tRBaWkiMF2qFLjjcf731PYdqtMyR+Siq7J5hKMcfKQPm/H+dHLZa+X6HLUnzvQo3xnaPbC226EhZwTkkZ4PHrVeK3E8V3cy3GWMg8t26k9MDjpVqcx+YWEm9pG2KwxklqkmnisGDXCgsD8gTHQdxn+VZyu3YabtZLUZZyLDFtbyS0gHyr97I6g+1Z17E8tyWKxkru6cgn3+tXY2We6lkZDCAwzkYBB/wDrVFqE9ti6hjCNJwylh90EkdazlHQIXUtEc14mJEyRrJFKQPm2AkdOgB64qpptkGQSSNsiYjAzxnP+fpVnxU/2C1V/l3qpLFOnA4I71y+jaw13KySAhVxtQ9Oe/wBKqScldHpwfuRVzrI2AuC25Jdh4Jz+fajYLn91LKgiZuWOSyjr19KghUspJZt/LAtgEHsRUWmpOk0scxdV3AkNg49KzSuNpau+p0tjbiSJ90keyFThB1Y9iT61MPs0NyA4jyAd5U4+THO3j9DTdMxdISCE4xkcZJ9qdqlsv2GRYWDeR88oBzvx05rWME7HBvPkbMtGtrM3E0chmmlA2xsMryelWZ1gSFthdGLhQzdF/Lv/AErKk12GBU8yC1lMke7av3kXPTPrW3NfDU7OSVrRysxDr0AOBgVo6Wj/AK7nRLmTTl1815FGfTmE6GcwMcfKqNnjPT6d6l1a1VWMJJlmBB89WwCO49/rTLdp1vPMaLaUURBGwVx1ye+ferdwJHtrgXTPGwXIKkZAPYVjo7oOaSkrsoSzW8sCRxbzAj8eZxgY9fWoLFBFIzSJGHlGwseMDsfpT7CZorYiURzJKu5VXrnpyDVy3EVw/lzEEN2xlVGOlRr+Y5Kya6DreKJrUMPkYD5Sx2l/w7H/AArB1OdvJJYKzRqAu7sc8/hWiPPjRS0jMgPmRD1PTj8Kp6tbm6ZjtyrAYIYcj1+lVoOC5ZavQ4MeLSNQltm2hQchzwzDPbtx3rsrXWYZ4iYyd5cBlVgwOKzLjwvoV6kPmtHby5LPMUOxM9Bxkkk96zdX8L3mi6jANG1G2vI9xQujEBMDJIBwcds11uhzR5onN7WpztVNf6+46q8mjMghRAjSEBvQ45q4jz3A8oYjgypDv0T05qn4fla+W2kvl8uCFW858cng4x9TxT1m/wCWcqz28M+WTPQgdvrxXNGm7X6HYnzadv6+86A3ktoTDPJaF167Dlfw9qKwYVtJIlKBsY5GOh9qKtVWloJUIW13PmWT/WN9TTadJ/rG+pptfRn52Fel/CjTIpbr7cAxVJ449j8huMtXm6Z3ZHBHNe4fCOCFtCginlmLOHdEUjAy3Xp14rkxjtTsduBhzVbvodhfmK0ikRHV1O44wec9Bg9qq3l3GkVvcXMm9RjP/wBf3qO5ia41SOaJHkhhfADkcmqWpWT3UV1DPKY7cuNjdwvf9a8ppNn1lNKKtubOj3LXbi6BxIZdnljgFMZ5qe4u3uPEXlKCsDE9eF4HWsiyZbUSFcoUGEVTnPb860J7QCXzFaYyyHLAsM5x61m3Z6GnKld90a1xFJqujiNZokcPnaUPK+5qhpNpJf6pDu8qZ7ZipRuCB/hUcerm2uhFaRybzGN+W4D9CQe1T6avkwM/Md0HLKwbG5iMY/Lmojra5moyjFx27fMvmDcZVtgdoyWlzwo9PzrPI26hMqBRIY93mbflHt/+r1q+63C6T5Ynj8pf3YfOUJzkge/NRRLMkSJIxcIp2lj+ZFaNqTt6dCou3X+v66GfdMzyxTRtlwymSNQR+H0q9GD9pfUVg+zWqBtqN1cnsAO3NRm0klvovLYs4OxS7gGMAE4z0zUyzfZrV5C/nsYuSz5Kkn+H0ppamk7SskMKu9ulzsjndAAI4xgZb19cVdtHkuJltppFS3RVaQHO5l9P61X0ycmz3oT5JcO4RgCp+h7VYcSpM80DkwSDOARzjnn36UXsr/oRN6uLLb3EdwVgg2oEYlAc8j1x3qtdXqBlZm2PI+Aig5jx97I9MVa0tmup4vNkAlZCdxYAA9R7iuYlluYtZlvmLSCKYB8SAhQTgf5/lVSd036dCIQTbXb+vzOjuRE32e6icNFGMr8p5H+FPs57e5c3F8sNw2SUVhkAY6gdsVna1dyXFvDJbSypNECNqsAOetUrOeaGMF4SHyCSXHBboRWOkUpISpc1PfU3rouLpISFETnCEjnbjsf6Gsi6kxGA0cZ818DIO5ecfrRcGaW4T/Wfu8F/3gyPw7/hSXdq7ySXSDzWjOAHbjnO7NZy7ouEVG12c54uBmgfyYgJCOp6ZX0rP8OaNFYNc3BnaQyqoRGPGepxXTfZGuo22kAnBZWPAHv6isv7I8d4kciDaFLAMw9a0pz0cTqXLKyvrEsRpKyfJtzkkcYHT3q7HBHIc7wEKjoCdx9PYZ9aoaTbTLtaWQM8kv8Aq/Q/wnr6VqxhhEI1HlTM/B3Dn2pzXKKctbJmvFbpHaLKyoZAQQi53fnT5biFbItEkYDSKrLtIzjOTjsagRpgyiQEZXLMG6L3+pqy8ayXiPLlUXAIznJPQ++KSbWqOB73bucxqGhlPntox5L8lSvPv+NT6TeXFvY3CSWwZIH3KQMEPjAJ/Ct/VdWK3xt7i0JH2ZtkiONq89x71UsJvOSeIM0TspU5bII+vce1bTk4x3/A6fbSnBOotrEqz20tsHMexmIBK9cVQIL2130kOOoHT6/hUmmXJmuhC8iZL7gWH4D8Kp6lFLA05iPkAgqux8EjPJP1rD4tgpwSnyXs9CnHDcNEgnBW2x5gP94DjI96vI5uLTLuqIIhhSMAAHv3NGlRPJGgSa6M4X5tsgGfQDNNSWfypIWJaZI/usPu8/d/rVODS5jocuZ+hHcagVtIxIqy/KWG/Jw3rx3xULziOVWiiVWkTJI5A9iKZJOVZYZEBiU8IvygnH8qbZiGedUtS0ShdzjdlPYAHkVA3FRjqtCWziLzqcRkopOQcAnng1NJpwlkUyxhw4Xf5XTHYE/XsK2JbSI2MMkaOwkDbo1YBgwH+eKq2UsEdqgvHaMF+YkyCMj7wrZxnHR6HKqvMnKIul2trHd3W9oltYFyVYHLtnpj8uaoQZk8y2ubrNvNPk5U5QDuKuXkqEoxG9SNuCwyw6jP8zVeeSTb5reYjp91wepznj60Ko4qy2/rzLUZNXe7/AVoIFdltnkjhU4UdeOxoqC1J2MYvNALEkK4UA9+tFQpJrb+vvNOfl0ufL0n+sb6mm06T/WN9TTa+lPzs0dGSOS4ljkAJaJgmVJ+bHHAr0/4WXd1bwWRtUYvOHWR3GUCgkdPWvNPDgk/tNZYg2YFaYlTgqFHWvVPhjPEIZS0gTb82WJCgckjH1rgxj0a9D1MAm2n6nbGGU2d1NaSFLlclkQZBHqR6fyqlo6m+0+T+1GDAtywGTkdj71sW0sMNrDduN6uSm4uAADnt1/Gs7SLWeS0vYdyLCTlCDhgR6f55rzN0fRx1hzN21GPAr6lIqrsiJx93I4HXA/nS6ldl7dckbSoG7aRnnvSfbWCqhCoEfZIM98evp/WgxvdafFaoqSLCC7L91sE8DPrUXT+I6U1vJEMF/DeXcdrBjcp3OwGcj6f0rpbmaC2l+zwcMwEjFxkqe/4YrD0PT47NxOkCR3HllGKn7w9aIpP7S8QFrvP2cLs8snaXxzUrX4TJq921oi9O0t63lxSx+TF87ZU4ZvX69KY1w8tvF5skZXeWJ6YOOn0qO6eW8NzcW0IhtziNQgwM57j1rSfw8bTTI55dsk5fBDNwvQ8en1qo023p/X4Gl4wtzOz7fIdHdSyZtvJVbdgHxt5PoQPX1pbizSHTQ0ZD/NsC44OSOf8KiubzHzFFMgHBL9OuCOetLp1z9okniuAqRpnauSQe+M0PR2RFnFcy0RNaWRTUri3EsXlRRgYXkM3Qn8utRbcvFDAV+znAL8hvp+NSRf6PLhyFR9xADZbb17elUZrmVZUlgACJIPlY8tzgE0nbYqMW29ToLKTJnmeKPDK6LJgEDA7c8Cucuz5tg7NGoRztOzCguOhI7irCTMhlimYIzlyG5IY9+PT0qtcWn2aONZ50zKu4H7xTAyBTUr6IqlBRlr8vkW9OuBPYyCSNE8mNScdT6/XJqzpKi4tT5irlnJOD2Gecdh6iqNiDJ5RZM4Q5PJUgD5R9anlm+y7xGkXlqRnB5yeT/n+dZxSJmt4x3ZY1Z0GtLDG0Il+z7iNnYDgfWq+oK8kDJbK7sxy+DgY/pWRcxY1aO/kZtzYCsrfxHsfX/IrRtrmVJ7mZlViEIePcR1B5x/SnNxb0KjBwtbWyX3ktssUaLNHwVHzEn+IDt6YrOnVriT5NvKHcGXDDvwfenXqItvB5XP2g72Cn7uDzkd6hs7YibzPM3hlK7S3K5P9f0pT5YopO3vX1Jbd5TZqsEaiR8hjjO0f57Ui2928sCuqruYEMykEN2rbtbJI7lJI5EZHwpUZBXHGc1X128e6uIjaOQIZFjVeTuPrn0pK7vd6IhVrztBaGhaHzoAjqs0gDDGOo+nrWh/rbeZd0ayHBAK/MPXB7YrP0jZbTOWCNMX3KVbp2/Op0kZpJHYKu1sebz8p9jW1Nq2pxzWrsUdZeVkupkiQI4EZXHzZ9R+XWp7dYjp8JVilwoyxC/MW5yfb0ouhA58yKSNp0XeIw2A49x61BFPM5lfb5br++c5IDjGOAefwok2a2vFJaW/4BQKF5Wmhgysa7mAbaVPqDRriR3M0Ua3KSIUBUKNrZ981eSSWTy4ZzHbuEA37SwHOcH1Ht7/hWVcadPJfi+iWKeNcpkH5c+nsfaogkzppyvJSelv63LC2VzYI86sSMA5jXODTIpJUsjcSxtEZ13ss67nDZ7/410lnd266e0bqVRF+ZZSQe3T2rDu7xNR1GGGBjGJhtLMTwBzgn8K3dOyWv9feZQqzm7yjtuzL03RX1i4nSe6EZRSUJ+7x6mkfTzbXMaWQfcuBJxyhPGCehHv0rTkkMVr9snnRUmlzsVSmTj72PTtWrqkdvq1958cjW8tvahW2ttyV5Ct+dFWlTUfP+rdTSpWmp3l8L+5dDPimVZZIroyB0wGdxkpJnk+/bNSz3kFlayyTzrJczB4lGMqD/eHr19aqRlry9mMMHnfwhDkb3/vZ/pUraPK1zH9pt4YwFz5StkKe5zUUq84rTUhxgpe9p5FbTYhcxhpIcBVOQgB98mobiKMRtLPOrozrnYpUbc+h/pWtNZfYbVmBRo5RsdwcFOeFx39z3rG1COCKZ2CG4jD4R1JUKMdAKiyXxGtOXPJ8rIDcJvbMNsACQoYEnHbvRUqRq6K0pQvgA/MF/SipVR20j+JvddEfMMn+sb6mm06T/WN9TTa+oPzY19JnWyt7xjuE80XkoM4G1up9+nSvV/h/oyp4SeRyzXF1gHcOPL9B75HWvMJbeOPUNF85c28kcZb1I3EHIr2aFf7Oe3ggkUgRnauMAL6EZ6+9eXjJ6JLqe3l1P3ten6m1oEcepWFoWXKM58pAecAkYP5Hg1o695GnW5aJSAIy6+oI7nHXpWfoo8nUtMVSkcIjZMbf4ixbPHfqKf4lnhupI0jch0UhgMguc9687Z3/AK6Hs0E3O0tjlNFvfOvNPN4nyTFsjG4E5yM//XruDIgH7kBN4BboCXJ6fXFV9O0eKWWaef7NEkMeUVRnJ7HjoKr2IW6ad5po2iUhRxnce/HUVLd3c1bu7t3LlzbyQatbw7/OCgFRwfl9vz6VBGS3iK4uICoBZlVR1yR6+ntU5aOfVonjCvBDEd8jqfk9On5VTsZgbtJQqAkZ29wKIytsaRjdNvex0mlWsY0hbdz+5EP2ncTj584x7nFJcytqFiLhpfJgIOUYZ5GSMex9PxrNkdZI4vLUkGLy9vK985+vbNGogLo8CoCYWkKlt/IAHAPt71pCellsZKn7ybe7/Qis2XUMOYAFyCAcd8g8+tX4NP8AsTlolLJuYK5AGQO5Hp6VS8O8K0lztijjwjBgen07/WrE2obb+Ty3V4ZAVWNskbc8f5/lUJJ6y7ms03JxjsRwMZr1HUYDFlVtnJUelVNYPmWlq7hVu/tLwmJOPlUAjcfXrWl58KC22GIE7gGH8A+tYVxGsGoILl3nB3Pvj4+bHUf1pLsy4Xcr9v8Ago0bi4iAhfb8zLvXaRx7D0+lLPJbiyV7hWRirIQACcnuPz59awoA7arbRAfKIzjb1z9K15BHGPLuWzjI+ZSSOhyKUrRlpr/SL5EmokmnPJBb2oMuY0fG7ocEfL/nt7VPbx/aXvd4UFQWPRc4B5+v86qXziDRi7RgPvyrbPmA7Z/WtIRWk1it1n/WxHJwcE47/j1qEndL9TKdlrbf9HcyGtfPsIrp3aOOE5CH+Ij/AD1p1rIkpkuMYZW5bPByemKLuU3vnBGWGKCIIqLnEjY4x+XemrbS2ulW0cqqxl/fcAbvcZ7f0olZK3U01tZ7v8FuQzfLLtgJdM71UrwP7wz2/rVuKRGtpfIj2M2G+fqAP8/hUMt0Y7eVo4g0pIVAvQcdB269auwQMyBZZYUOz5spzz1GaNN3uKbtuXdCgEspe+byYgN+BxnHsP8AJqOHUrK01ExrbyhTJtVyeATjt3+tV2SaVWl3kHO1Ao+92x9PanJp85n+03A3KuABGPlHA4xWspwhold3MHGN25vfobsM1qsCoEKykFgwQDHP0pEna1hZfMhaNn3lHQHPHX8/zqvAjMkjrDuVVIDMOjHpxj0qeOxVbYmZFMaANjaSxI7DjitITe9jmcUtyrcS2Fla3RZD9ofhQRndnnr6e/aqD34njjuQCI5OBvx8oAOMjHIp2qRlLOIlle4VSCGBPyk5/CoNQtXMasXUJGo8sou35vpWMp9DspwhZN7v/gCpqCyWk7tv8/oVxnP4+lTWwQrL5TXMcEkPnlFXGJAMdP8APFV47QWTNHJLiQ4BBJw4PJI9O1Rxq8epi5WRvK3HCn5t3GPyqFPXmkNqLvy/1sXdH1OW+gU3CoZ5nEAUKPuAfzyKnnsLeB3jhCCZ4wDlQ7qxPQf41T063NsXIRH2D+JMdT0A9q2LJYbu1LMsNvcE43uMk985HIrqp1ZSSTeqMqjUJXjsZiR+YYGm/wBLS3zH5b9AuOAFPuelWdelhu8m3ZIiURWKKN2B6U+KBZ1UptQIdxfaQXPt7+9Q6iqR2blRiV22EbMcddp9896mUpS31FdSmu6DwsptTdzw30tzbx3EhSWVNrMNvHHr1rVLLIygMVEaklm5OCD+f171gxSiGF4smJndjtUkgjAwfQc5q9p1y8sbzSqpZ1Akymdw/h4HTBFTGSb7XIqUndy/r+tx90RdSwDapUJtJPG45PJ/PpUE1s9m6shRfnKgFQcdulXwlvMJGAUBW5VAdvJ5NVPEMaoEnRk2GQ/Mucj0yvYU2rrmHSleSgVIZLFIgs+nCdx/y0Peis6/W+ecPbXKFHUMRymD3GKKUZ1EkkvwR2qnFq9/xZ8tyf6xvqabTpP9Y31NAGTX0p+eHVXDwz6zYW8UQRfsiQktwNx5yfXmvU/EhfT/ABBp1lMImkuI9kzqMCNSByBXB+DrP+09T029mQtbxr5JZ+cP2z6966bVke71JZJ32StgQGRCd2B90kd8jj6V41eSuo9kfQYXmUXJdbfod8l0YNZWzaNZEVlWFgQufl6gYzk+tVQgk1FJXHmSEFVPGN3+PvWeLwS+LLBQoMqIS6ryAQvTPfOelbsXkicTOrC3V/nBTBBx1GOtcconq07RukuxDBdfY9Q+z3CsIiDG+XwMnkL6Y71Dp0QsLtLkqCq3AUr0Y57g9jVfX3ku5YSqf6x/3i7MAke3fjFbGpxmOOBPKDzSplRIM5P97HrxWT02Np72fVBq4jtTK8I2xOxYIDglh24rndNW6Ji8wr5wcjAIIK9hW5d2k97p7RrFgiYN0yAdoyB6dBWVo1rLFcsZkLiM4Ynjn0pq3K7GkJWhrv8A15mtG7hkwy7nJQq7fdPXPtxxV27hW7tntYz5ZkbLxtyAAM5H5VHZ2sEd6RIjtMwyCwzgjqR6/SjV7xEkgeOIEgEFl4z+nI9qINW1Iu5TtEzrqeYbjaMGjmG0sV+Yf59ap7GjSB0b98OGO7J64NaOnhpNRXzYpUjQ5KhcFvTH+FdBBYRCztXEURnlumhyVxzjIz7dhV0oe0bNpVlS0f8AW5k39mILmJo4RJGEAfA469/TNSzpC8UawxkSLuWR85UHjoMda6e6ijXRrlriBbdzP5R2Dqw+nT8axFkgGlXYUsLkzbQChTIAHIPqfSt50VBJf1oc0Kzml5OxytjE73BmVsHec/wnA71rXoMzzxWx/fy7FUSgnHp27moNMMm+Wfaxhjby9xTG1vc+g96md0tJJpprn/SyVClG37gPp069KzS6x1R1VJSc/d3X+af4DNKmfUtNdLmJY5EYxS7juBI44PbtimaheGPSI7AxsheTBk9VHQA+9GjGZxGJUzA7u7Js25OMg0/WomvbhEL7Ej7kY28VKklJyIglGpZ6palaxIjs2dELsXBCZwQB1z6069W6VA7Kyu27PP8ACeg9hWhbo0VoVSFHUYZpsDCLnnPoTUc26S5lWSZWRTu+UYGOpNY62ux8/vXQlnbKbdHU5XACqeQp7EjvzREBIkpmzt3k5Y5wF6/WrlubaPapGJgoYAHAbPT6e/8A9as/TluriSaCJVWORt2CBwqnLAH3/Wocbdf61Ive8uxfsw3kwQqSsm9nJDdMH5fwrRkmli00KFxtyM7+X57e2aZEvk3McRTNyzHBVMbRxgfQf5xTkia4uVITFvbD5yRgFhg4x3zWqi1scs2m7vbf8zR021mEZWWXKSIcsDgg/wD6qq6vLNBZJLauwJxGq7/vnHT3FWIZppdLmUgK6twD3U859R6f/rqbVXlmFhLDFG4VlwFAOwYxnHtXQvh0uc8ZNVLyObxM8FrBKpjluPlaQuOVJOcZ/wD10l4Wiso2LiRJGbbITwTkjp3xjpWldW0sjQRzBFtogSxIy2cnqe2fWsHXIlYGGOVcREGPIwp9cfT1rG0r/LyO6i1OSX9f1sW72NvkmBLkxfOCN4xnAUfzqteyW9s7r5a+WCBGWfd7nLVc021nNoqvtKhBheeDn7ufXvmjV7CJpY441QK2QyHnv1/pUSj19Apyip8rZJa2wsxNM0jy5IPzvnauBjFMupI3+zifi2dD5eBhic8kn3q4tuqxkwhQqkIAV3ZPGAR6VGI0ivjbqC05j3btvmrz6L2q7dv61M1NN8z3NGGNZo4zBujmUb4RHJtMeB0J+lR6ok11GIEMP77aZN2Mpg5JB7fSoLSUeWAqxeY0gTOR1xjOO4FOvFeHw7JPLBCrPLsQxEO4C4zn+ea2b5o6djGKtJd7mVLaSRTtDgSkJsjx0POT9OKvWEgDl4Yd0K/fBYcMB6dfwqC/n2rvhc3UoJUsRhXI5yvpVbQbhjBcNM6h2J/g+YE+vrj1rJJc1rnTNOcOZmzHKlw+xvlSVWKDPzAjJz+OKyb27UNIkkYLSgAhDgKQc5PY1oWV3Z2kD/aTJFKqFYZVj+8D1HvkVk+NJ0t9K0+OxEUckcqs7owbzFOCMjORwcf/AKqdm43v/Wn/AASKUf3nLb+lr/kRLdQyFmcsoLfKAccfl9aK07OKzu7aN51Tco2gKmQB6cfWirhXqKKt+hTqwTt73yPkKT/WN9TSoCzBVGWJwAKST/WN9TVrSUeTUrYQ/wCs3gjjPTmvoZOybPiIq7SPRdOgl0fVrPT4oJH/ALT2GFMkbHIADexyCMeldXfRi0vrC3SMmYHzAh+8WB756YNQaXuuNU0bUFRozabWV3OWHuB/StcWH2q9hvpXk3IpRpDydueR614M5cz1PqqEGrpbdP1Mzw7EJvEWoXrIYnc48hju2k9CD7jv/jXTWp83y4XaTCS7ggyxK/4/571h6bMn2fVbuAfvra5AJ2ZXG3G4v0Hb5f8ACpdBne4ggnRZY5EcmTJ5Vhnoe/0rOab1Z2xSV11bf6nX38AieRooGVVyW3SZbd+XAxWcynWNQs5rlpgsZ+VlbOFxgH8+K07+SaG7iKKWjmVgd/f8fWqOnzCOaIWm4DlZFYDdt78flxWbXLLUUU+W5Fp93LNqM1mzusTTFJMNtAdR98fhWlLZpGLeNUzPLNg5bnJHcfhUGlo9pdzXIiMxJf5CMsp46invc7olaRZUlz94HOCB9PSloxyT5vd2H21xGD504YKp/dOfTocD1/z2qC/EbXAe1QFMsygfN8ueD7fWojqUCzKr/JAqh1DIHIOfT+lYt1qUn2rNuZTDJIypGOMjrjI7Ukrpm1Om7uR08DO9pJI4HyqHUhvmJJ6E+tWIHvhZiO1uIfPWcSEyMCMA8kN+ePX8axdD1OUGO0uBGEd8o2AMMOuT9Oua6hVS4v5GjjeKEEna2MYweV7e1dFNWskRWvBuLQa0yW9tqCqN0U0yuCZDwc8/XHrVXyEe182dy1vtDg7hnOccepNW9RnFzLBa20SMWBO4kfKccg/l1rLmhuIrUoGLpcynykYbfLfOM+w9BWtSLlJ38/8APsZQT5Um7P8Ar/Iz0S4k89IQqrKCGRX4XnA3VnxaZJp/iCO2vyAYpk37G3jBI6Afqav6zLbaPA2m+a8l1OIWlkHAWQPkjPpz+NZmnAXGt6o4aSVYpVeR88YHQZ7GoqUnThtrp+p1qpNppPR/5b/obttKLnVbwhVjiErMoZvkUZ4A+o4/xq8kK3jzq0UaruALZ4AIOT9B69vasXSD5em3tzOd0JkGF3AMTvHAP0qzFOX+1xWoMZY4zv6jnAz64496w669zKcPeaj00/ISeO1gCRymd0DLHsWQosvPHbkDriqqb5LqZII1b5WDFuAFHUfSprmCXzngnkZfs6rIBnk5HH41bjC2ULTAlnmDfNIflA5H4daiUr6WtYu/Lru3/wAP+QQCG+QmGILNEqjLN1Xv8p9O/wD9erltbCCFXgQJKWP3XJLKeoI7544/nVRpIo3EUMim42LHlQMfd5z9PWtTT4fNt4EkyAFZlw3JOf4vY/pQo91/WpzVXZeX/AJ44N18NilZE6vkkAY559O1SiFpJI4VdEtyuWw4OSccZ/Uipmim8wSyMxUHZ8rAcccn6frSyS/Y5MrEvzR4jCkHI46/4108lmzjcm3oEvlQzzMroBDHtT5/v8DJz6Z4A/wptuQkayOixhQCAG5J7j6VFAJ0lleRI2fHyRnBJHXP58YqWC5hje6Mz7HCjauQR05P4VpddPMTWllqVb7a5nuNhRljyYyxx1447k+lMitba6tkjzarPEd212xj8D29qztRlJjggijkZ2UmRlkDq6knAI/r2qF5za3sAnlDNjOSoyF9T/eFcjmr69jpVN8uj1L815AtlE2zazoVCxvwXycgjscf55rKF4b3WI3hdfJgON7gkNxU2qwmNFhDDIPmeWwxlsnjPbimWVm0BbDK7SDzCoAGeeDmk+Y1goRg31exoq8guleSaIxb8legyR6+1Me3mi1UyRR5Xy8ttfaWyen170GEYTe0ZK4Z8sAcn0+lNMyyTeR8/wBqMZxtfHzZ7evFPXZma8uxmzyzQXEz24iYFed54Uf3h6HtV86hAmmNGltIpEa8NLljn7wH931NVLW5mW6gjhtm+zyEM7HDHGMEgHqK1r+2htbSI54CLIyucnf2QdzgYNKEZJNo0qOKcVJHOfa5I0WImKNHzl16sfXGeM4xQl1A9zDC8oimVd2MY39ffrSRbLi6lkkC4UNjb/ET/dHelIitnQPEDIVUMzRjIYZ4B9PfvWsIJ6s6mlqktS/qrrfxQxhghC5z5nyj/A//AKqjvbOyl06LT57i3wuXEqL+8yRxuPXHHFPSONLdzKSWYkkKAOOoHt0qnqAutWLtZxMsMDb/ADAgyeOM45x+lSrO8pGUFZpJ2SuXtMsWnsYdsIIjUR/ISvQd8dT3z3zRTdNa5W2CQTQyKhKs28Lk9+tFTCEmk7P7jCUaifuysvVnyZJ/rG+prY8IIr+JdPWRSyGUAgHGc8Yz2rHk/wBY31NaHh95k1uwNqjPMZ0CKvVjuHA96+kqK8GkfGQdpJnrek3T3mta9pQtSbq2hLpiTGCAAcD8R0rQ8MzXBt72yut8c6MkZcAsVJXJJ/QVDocn9l/EOZowPt+oq0ckb4AVSBnk9Oldb4YsFhM94zkC53gk87iOOB+FeJPl2R9XSbi230f4a2OV0TTp307VtJlZfJvLzMhZ9oYbeufTrxVrw9ZCxsXHmSy7XZw/JyvAJPtSand/aWaJC8Jkk2q2MbW9R6/WrHijdYaf4V0+GZfN1AbJ54zwp3MTx64GMGkrz0OtqFKSv5nURXFte2TbpMNkqFUHC475rOtwyXjEoQYyH/pz61T0lV0fWZVhdxErkosjbiOO/v71v+ILbFit/CwaS5A+4enPf06VhK6laxtbktHpIW7lEMrKGAMsWchsbRnoT3qpocck8bxyEsY8u5ZTyCNvFTXcJuHtkI3GWAFyPZsdfw61oWkcUOtXKwKy2sowoVjweKHa6t0sZSmlDz/4Y8w8VX72L6dYombi5+4QPmCgkZ/Suq0bR3h1TSba5ACMoXexIHU5JPYe9cb4yhuofHOk3cY8yRYyI0b5sYc5/HFel3t01pJdwvKZkDM1ndq3BB7MD688e9dUKcHFS8kONSpKpOC+XzS1+8taleJZQahpVklpIrHBliwzKM54P8wKryypFNDJBmO2eEOyBSx49PT1/wAaydM06bUJELy+Qs0u3ONu09fy961i0kHiRLCwjNzcfvLfyCdw2bD8+fbn8qmpU9s7xVki6kYUtFq1dv8Az/AtHULeNzNHEiwKQoMZLN37/iM1FqCz/wBgT6jLKTLDIEt4wBk5IySfXHSqGjiNtfhh+WO2x+8QnhgoJJ/Eik1XUryHQ9VS38swyS/KjIGK56MP88VrBq9ntr+TJdNqajDy37a6f5mVdwC5lu5xNGBEkWzKljIzEkhc9xjmpVWSysXjEWWkk3ZI5ORyD9PQ1YtLWU6bpFvvjLgj7zAfOccnuauTyJYXYgk/f3LMm7dyHZmAOK560nN8z/rc0jNpJvXr+n9f5FeCzY6MwdceS+8FTx78etN0a7iju1E6KEecBX7hj/F9Afyp8iS3NpfebJ5MEVxtYRjLH5u30rBtNSSTxA1vC+7yiQQR2PGfx9KhQi4eaG1zRlFvXU6qK1nnW/v2xNtO0NjODk8/pVeFpZrGNWljEaMzMHGT7YqwZ5YtBuIHkEe6ZAhD4ZlGe3ce1ZcQluneH53l+ZsKAOAO5rOpCMYqUd3/AJkxjKV+bv8Ahb+vmamieRFOZplMiYAEmMHPf644qeymnhvY0YgGRwSf7ozxx6kVJa28ttaq0MkZZyitC+CDnrV3StNjhvrh7hstnJAbK5Pb3xSUJPS39anNVnH3pN3uX/tXnJcNsVv3ikfwkADHQe/bvVR5EN+YiSzrtkQAHIOBwasfZVjvZJY9rPKyqy+blcAdP8/rRY2xeeUhdjYHzF8ntnmuprmdvP8AzOVcsbtGix8xCERIxgHJU5JAHU9v8mszXWtI7oAtGjSRKJF25wPZq0LVfId5JVC4+9h8jt61z+tR/bLtJtywNFHuTHI298+vNayimrNE0Yrn30LWqyxpbyCzC7hDlZdmCPbPYmsKx1Cz82WwMfn3TICJHGTn8emKsWakWbszO8sgIQBuw9B3+lZ1npjJcrevAwlc5U5wMemO49q4XNJnZThCMXFv/hzWlure30zZ5ZnnKbGYjk5J5J9c96g2vH51ygRRbjBRuCemOD9elVprWWOJhIwjONpOecHngVanZPI8n5JS0mHfOQTjpn6VKblv0KUUttf6RHZTNLdJfeSWLPuY7SVTjAU/zqfW08nVlubsxvELcbQnAyT0yP505YZFlmOY4rOaVZNqNu+XGBgms7UrFzb7Wl2xKCWfPJ5/TtWvNyLl6jhyua18v6/IuCC5lvWyYUhhX5CrnlQOgIrMv/EBkeLKERGUo0bE5C7cZJ9a2Ga3/sfbZHzZUhyzAgYb/CuQv50awLnTpQzKqo+5h82RyB3zVR1u3Kxth4qprNbaf1r8zf023Tyt7Yyo8wAr17f0zVa/MRMZlS43mVmOxSRtxx+tW9PVLZ4Y5o/Im8jIZpCApP3jg9OO1a9zHBNYJcCVWBg8tBuGSBnB9uea0o0/d3M5VnGd3fUr6MyTWYWdCtwBuY7eGU8fh3qfTbmPS7t3so5BDOxjQyqdhwMKM9jyOKy9K8u1tme7k2GRvKkLNjHBIP4miW2eW0IuYnWZmMi5nwoXaCpA9c96iM3CzRnKmm3GT0f9d+5jatYlr6QmSOOXJEieYRtfJyOKK0Egs5133qSSXHR3DH5j68daKz9vB9DvjX5VZr8EfK0n+sb6mtbwzMsHiLSJQjP5VxG7BepwwPGKyZP9Y31Na+g2yPItw0jrJE6sFXjcARnnseRX0dRpRbZ+fU4uUrI9MuLWePxfFfSbn/tCVkt+MlSR0+h9a9h1JFi0fT0jXZOECbMY5571x+pLCf7OuZJImj08i43ZHQDqfQdq6TSLtrvU5bKVfMSSJni3Nz2xzXguTkrs+mcXdz6b/eZmsWMBX7VHHISjCVmCZ5Awcc9PauW8Rut7GktuJpJdNdLvzNmQmTjB56YzXd3qLLZPsZ23kFFAxgDIII+veuVs7SOW/R1R/Olg8qRASUkAfIyPQf560QaWr0O2KcqTuaOh6lBZ6tcTTwC8hedZ4P3XD8Y2N7HOfwrTnldNJMV1IySscxIE4KE9fz/lVCwjUXNnGYJLeBSYwg5Bkzng9hg/5zXTtp32q4EkioY1GU+YkgDg59Bz1p1KvM7Jf0zSU4xacv6tcznlazht5IUkXymJf5dwbPoD+eKl8yS1MkTM5mN0WSVFySpUfLj1zWhDa/bInEgEZRS2VbPpxn6d6i1axV4ZFtxkKRIpDE546k9s1n9lHN7SLfK9/wCv8zE8ceHopNLtbmwkbz9PuzcGcrkyB1Abn07YrNhil/s5vOySpyigZyT/AAk9q6e8dDHEkkYzsAY7ztzweR6ds+tVRa/uG2QOrxzMFGScqTkZ/DvWkmr+Vi8LUcEubdv+v68w0ljbwC51AeVOcoGx0OM8L09qW7ij0mCK+mcm5vSlx8pw6Rtn5eO/tTNSKTwKdjSOjGQlWwMdOnpWLr8k9w2mG5l2tn5wEwFVei/gKUVyrvY1jH2krvbW69NkvIQXCrqtwzs0cKuyswTkLjge2auaKFn0y780ExyEP9AOh9qj1iKCMs1sqmKVwoDc7l7NntmqUD75UhDgCNdhKt2Hf3rPmkm5PzOqS9pDm2/4Bu6BHE7TTyRs/kgCMH+8D+naoomjlvzcXqTsqSCRY1HO7tz9cVatLm1itxFDbhCX8uQmUgkCprRYbbRPOEaSTuzbcPkruwFGO/PH51Sd9zklLVtrfQxoZJP9KVl2hjv2iPGCx+b8v84qhZ6Z9nv5ZYoXeRiI1Jjwzk9OP8/jW2Ld7WFHuMb1BJyPvHuPw/ziokNxdTJI+ftCzIYVLEbeeB+OKjmkjeMtG1t/X9P1JrzdpgmsCitLHES7yDO1zyAvuORVeyjkgRWkGL1iQqBQPvdzjtin6jHPLrEsupRE4YkojHIbPHT36VLJbzqZJxJFblT5Uag7vqc+3pSm/wACdFFXer/FmvZRW6SlhI00EfHKdz3J7E84/wDrVqywwusr3IaFCMLu4I9CfT2/pWVZQSQQypCyNHtUBwxZSfXpySe1XLW3iuLVzM6TOh4IkLZAPPy+x4A/lXSnaNktf+HPOqWve5Y+zyTwBVYGTeoRkUDk9M+vuant5w0/kMp3IFyUT+EYBz7n1qvG01nGLZURxK4C7XxtLcjt2HUVd0uGOO+CFjuxk7uAR3yfXPatbPmsYVHZO/yLMumtJI4RS0R6+gHrj2/z1rK1Jba1tgb1TFG/yDKZ356V05SzkS6iO0kqVYK5OMgdPbH61zupwL5IaS3EsaKDEjscq3YdOvf/ABrSd0m15mVGfNLUwLCRPLa3ggbKgsZWOTGfT/6/apLqcmFtkaBFGDvOecHjOOnfNVbu2jt45WjfEs37xgGOeOM+3pjvWaDNPHcKyxjy3Adi+BuI6Y+nUV5c5yu7o9WNOMvf/r8x+rzztbxecnPyjd3/ABP9atXFsLWJEaEpKWy3mHapOCTx246VV1QxrewrEisDjc24kD6D19qt3H7+8lSR4pymVjIc7WP97P6YqU97+RpsorZGhEFlNvFbxCNdoPzLlvoR39aytVhleSKAM8kQbLAR5Oz1z3ptrJcSXqK22AM4wGYgDjAz6VsmCPkQhiIsqzFiA3uD2PtVvmkrmF/ZSK+l3NjCYrWOUb3/AHe0RCTsDn3GKjt7Zrp4oRJHPG8Z8tioJ256j3/pXOXwhtbxYkm2BWwszfLz74/Kt2XU3jaxS5hiiuJJPMEyDYUyOhAGADVwk2km7GtWi4Lmh1V/zOf12aRr147qaRzF+6hDIAWAP61stamaCS6MTCEEZG716Zx+tVNRk/tPUJoxDFI9s7DzIQSJOeTnsPT3q0NXtbHT5bF5vLwSV3jOBjgH8a3c1KfL0NZuVo8q16/0ivaslzqjxXSxzK3I+YBSORjPbHapjbbI4ZWVriXzDCct8nyjsfp2qHQIvMRTFafaBPISCq5baOhHpzV/yZxdC2KwRKHO2Qn5T+OOnvWNZq2iJnJKbt0/4JdsY3EJ+zbY4yxONuTn39D7UVb0+eFIWU3ES7XI5yc++e496KmmrRV7nnzg3Ju34f8AAPi+T/WN9TXYeD7SGXTp3cN54VpIiD0Ixxj64rj5P9Y31Ndj4J1X7NbSWKwpL58igqy8k54APX8K97E35ND57B8vtPePS9BvF1XQJrSRnW8mgDuFG7ZGTt3c9gcfnXfeHrZre3hacEzQx+WGPQEnp/I15/oVmkWq6jfI6qkkCJsAyOOoPt14r0vTlS5sliIVfMHU8Z47+gx3rxm1sj6FNqNpGQs9zF4htnjRn0+eb/Vngk4IPPXOc8Vo6ZHaR3MseyQOxIQkDj3U1Np2m2oluXm37lkDKSpBA24yPar1pocNvfWp3s4yZAMH5QM/MPUf400rtM2nVhqttPyLcenr9hTyjKk6TEMrKNxbsQPpVmKWGPWo1k3ojRMqk9N+f59RitSyVjJmRI1ckoxx3PrxVeWx8m7eURtwoBV1z36112Ubcp56q3bTGC38qVYNkqoRtGxcnJ7YrnRN/wATBomErYYFiBwa3b+XyZACr7GwMgYGBzjPYe9YuqJ5Mpm2suJPukZIB71z19lYuk979TP3ARsWjIjkOCBx8wI+YemOOKnmnDxG3O8shKlR/e9Qf6dKSQKq/MRhOQwXr9KgRjI5lZ085m2hVH45/nWEJO1mzoi03cjIZkCHDLDhmfOBk9ye1Z+vafHcxvLHJmaEYaJuCxOckfStK4uIY1VNpEsh37iMHP0/pWYNNn/tea9mz5Crszk9Qe3qKanZt7nXRlyvmvb9SUWk7adbwLGrlQjFSOWZu9Za2Mi6nI+UwrMzEYwp9PpXU487EjDYkZ3KMYxn8K5+6jHnyKhVVkkYHk/mD3pONka0KjacWV4tQGJisX7p5SxXOcHjNWvDyi/RxIjGNJBkhsHJPGR2NUoLF4Yro+USgbarkHAHetC0hFnYPJbbUmYAL1OWPBP19qLWbv5mlRxs4w0bZb1CS3shML+OcxQ7nOekmMYH+GOtUdHukmAmdGc3RDjnop5UY+hqxPpst3Hp7QqZ5TlpFGTkLjIOaWG1FpdvJNCkZk+6FGAoJ5H+NOTitbGaceS1/wCr/wBM3bNWdWKbn42u3AYdh9c0y8hms7J4pEAKlgF2ht2SevsPWq2l3A8x44pYSyfNz/FjsfQj9a1E3zeckYSSUjDkcqmcn8K1ilPRnFJ8s9dh9pcSW8EUENsZozbSCVCMKC4IQn065zUtpYtaxSXCPG+1RlNwGSBz9fTNUTPexKgUo7owjbcm0MScDGPTv+FX3SQW907XQhkGfLVY8Zb6evp61pThZPrb/g/5GUk1s9/6/ryL/wBnklbJTBTa2CR8vGcZ9PekS4tdOi+03srKzLk7wB34+tJZzmeNRCyO5xG7D0IG76VJJZRSeU88SzQRkOy7eQVIwf8APWuy3ZanM+0y5K6T3FpawRIpcGV5lONgGOv59Kp6q/ll1jxuwqjHOSRWppA0u2ht4raa1lv7gsWbzOCS2efQDpWT4kG950idDs5mkUZ2v/SnVg0r/wBfkZ0nepbp/wAE4vVrkW6NsRzcOCwUYZQvPI/HtWVZzRqssyEF3wmDyp7lvoKt+J4ELbomCDyyzBhhic/5xWEAf7OM6MqZk2MSeTkZ4H4V4NWMuay6H0VKEXTVnubaYns4ZBbszSA5XbnJ3HgH1/Wr9xYy3U8iNbxJcqdxKv8Awr1P9Ky9RuRZ6RElsSdq7ldRzkk8+ma0NAeQSTGYszoD8yjgJj7x/GqjHv5GM+aK515237kWn2U15rSs0ghgdwSA+0yD+77VfjlimikEG6GGN2XcjZYHHQA9aghUpYyTF44bw/uWz+efY4qe10tI7SJbhkcJh9sYJJX1PvmtVH3V3MZyTd2/JfIyrfT0ubi2aNGGQMO2MIe5+lXb/T5lt4onyc8Iyc49v89KuJDHBK1yUQWW4Bm6hEwMHPpnjPvToZ49628Ll5o870cZOewJ9alUfduynWk2pLYxhbpZxO0MwLFSykAHac9PofWuZEBMxldZkujL5gdSCpXHC4P45+tdvd2v2tWlllihIYgLtwOnGSPfiq1haQSp+8iDXKJ88YHzDA71dNOGqR0QrpRbev8AX5FTw3dx6ZC7XDvDI6tJAo4+Y9QB64rTt54mgFzflbe3bJKucysTnJwe1U7y1ijvoZ4MMY1DeXGMsuc9j6UagssSWhuhHdJKhI4wAnJByO2ab97cylGNSXMuuvn1IxqsVlmKzuZfJJ3DcmCPw7UVnLPFKoeNGRCOAYt/5H0oqFBpaSX3nU6NL7Ubv+vI+YZP9Y31NdF4KVX1NcjMi4aMD++DwDXOyf6xvqa634fgxXE10vyGHDq+M8g5AA7mvexDtTZ8Jhv4iPW75zBr2mLCUCXyByeB844IHtXZ2uonTbSFzGf3CsyyJyCM5wc1zL2B1LTRJEYsQAywLtOFJ57V0OhXMF/pM9sFlN4I2UiRQQy8YH1zXixXNZH1cUnBc2qTOj8P7tQie7DnyZW3BMjj9K6iGyR4Yi6hiFKA7sc5NYXgnSjp1gF35Xd8p2/d46f/AFq7JSqqmEfdszjA+7k11UoO39dzysVUtUaiUbi083aylwwbAyepxT5YPljkAYHbtbJ4zn+VW/LLNH5bsTu+bao6c9Px7UsgYBlkKk/d4HQ5qlpscqmzjdWEaTAkgStkAF8Dj1Nc1qF3vm3RvhSAHRsYDcZb3rqvE+nvcW7KmXeIEjYoO72+teXXl2y3nlMGG08jGCMivOxE5X5bHr4ampx5kbttc/KYZPmYsN7A8nnjirMsRgklTcoLvlWzzj0I9a52zuBHM25Sr5xkjj2Oe1bkMqyKpcyEbiMMoyePX+lc8ZMuas9Bk0css0E8km8p/q1wMgnqTTrm+/eeW0LDGQg3feYe9OjjkS7lld90aj6YY9T+XFZzFTqccpllitoUOBtHvxz3rZbam8EpX8v6sbklwvl7XYmWSMeaGPJP8qy4fnEsrKWxkEZ6eh/nRvNwBJGGXB2qCMEkdTjt/npTEbMlwu14iAmSo4OT09q0cm9/M1hHlTROu+Szkt/3gSZsDJHIFMaxKJgSr8pHBOc8CrjSbFkVVdhjzEVQCQR/LNTW8cpAumEhkZVIjCgAFsDPNDV9/wCtzP2jWoW7taR8AlpV28nO36VDqsPkwJKriRmxgM2cAY/X/PFWRJhpY5pHEgYAK4Awxxj8R+vvUl9Zfa9se12VCCzdDgYzx6nt/SlOLaf9dzNTtK8jk/D1lcJPIZpd0jO7LzyA3bNdp/o9lp+3J2uD5xD8g44Ge/ese4SJWkkhykSRcydw3bjvU80kIsmdGkaSXDgMvGQDgt6D3rSm3dt7lzUqkk2yzoTwzWxec7zvIR2fnr1x3+tbEMCXTzp9oBCgkjdkY5/z/jWHZfubScSF2cxqZFCDZkk9CORWpYIlwPKRG8xcmQsccdvyH+TXZS0hbrb/ADMKy1bRfgtEjkdlZWETBUbPB4yQf6+laQnhMQaeQLGMA7m4x1P4VnWV9bWjXFmkLBhIJGjkGCB6k5757VoxZvHYQRgLs2qrjjZnn/8AXXXFdP66nFUv9og1mCwkltI7CJJJpVPyo2NpyMEkU26iisbd4bkxwALndv8Apk89aNUiTToFvYnAdJF80RYwARwPfsazbmElnka4a5V0yZF5IyBgAUVWktv61CCulroct4nbfB8rANtOSG4x2x/hXMWm4r5UuDFncwA46Yx/9atfUoZWKq6hkAfDHOUGe/sKywZFCRAdSGIyfmA9T/Wvn6kuaTufRUY8tOyJ9bcCCKNmKsuP3WB8o5/OtdLq7tZSxBijaNZCjHlx2z7e1YtvbG6iE9w5AlICD1QHrn6it63jnutYuZM7Czl5nK5VY8AADNVFP8jGrZJJ7K/5r+vuNDVYrJdOWSSZomlxJIykHBz90ds9KXSruO/Ns8LiCSFDueVsFie5Hr04p8gjdDEkixh5BG5C7m2gZO0Hjk1W067ma6P2WzP2E73ifb2yOo/kK2s1Z/p6HEo3h/X+RLqMEjaLc6dbs4ludu4sQBsBBOfTpUmmypbfuP3BgiT5Sz4fce596kvJ2O2aLKKx2kkZ+XHA56jpWJogvCZBIios4O2RxkdRz9OMVpGV+WKGot0tf6/qxDqeplJ3gYBZHcqqwktn6Cod87kLEzFI9uSx2lcHkEetRXEd/a31vqOnGS0nDPHGw54K849eCeaLFAjrGAzSkbmJ5Zj6++aq0XdLf+v62PSUIqOltv8AO50Ma2ttcfaYZPMAj2kbuYwc9T+dVrJVm+0SQTEYIjj2/MCPQeg5/WrelSXceLnYXKqEC7ARt57eoyalnsnXVEgtpfsyys7HaNxAx/MckisV5dzg5rNxb+fp8hlrbQ20IimQb1JyAcY56UUsEIKGNr7zDETH5m0Dfj+L8aKhRilt+CMJ1YqT5nr6s+N5P9Y31Nd18NZIiZYJsEPMgZT3U8cH19B/hXCyf6xvqa6v4akjxXpjMskkIuow8cf3jk9V9xXvYmPNTaPmcPLlqJnsegX0mneNV0G/hU299ErREkr5bDCleOx649a27aM6XqVy0SARkMFXdjv0qCbS21DUNM1Zll85JmCuQOCDyPoR+tdNqlj9tvbQQgmZGEq54JI4weetePHXWPQ+pp1FCTTej/T/AIJ13h4i6sYZi+yRsbkH68enQV0W3GzLYyDlepHoPpVbSz5VtFtL8/eAA+XHX/61aUIRlQ/Mdudp7d8j/Gu5Jf18vM8KtU5pNjP3ccQTfjAyTn/P50nlxmRQWGGY9DlTn1/+tVs5IEjFyDwBnr1/WoWBG2JWJROCe/Wm4pGSZh6hbqWZEcfe65PJ+v8AWvIviHojND9vsHAvIWJMX/PRcc//AFvpXt1wg8xvL8wYck8dD6Vz2taejo5Z2MrnkkDnp1/piuKvT5veW56WExHs5WZ4fp14lxZW9xA6+XMMrvJz1/pjmuhsJVkiBUlySdyqeR/n1rktasm8NeLZLOdXjstQYz2xHzBJP4k/IZre02cK4DB+H4A45/u9ev8A9avPnHldz1JPmjf+v66nRpIEgEaKXlLDkc7h6/SoHhiPmO4/d8nyw2T7DP8An8aapEwjbc6spGHYe3X+g/pRP5ohcMZWkU5JOAC3ccdwOacWiKba2ZDapHAHd3I3Hg7ifwH1/wA4qwY2VZAQmXPmDnv/APWpYvtGxXYbreXLMW4cDs30PNSj93ESAx4zuPPy9cH0x2961Xf1NnUbeu5BAZZ2fbkKhIYv19OPWtaGQeX5MrEGMKFJznH+B6e1UhFlWlcyB3Ynb0znpnn88VpRZlR5BuXgF2yCrAd/x7H+VaJNX/ruZVpJmHrV6LEJKF5km2sq5LAcevpnn+tbFxcyoLTC8SY3LnnGB0+vX2pGt/tBY3ClUj+YB2z6fy4/SrlxLbTpG7tIpjUbQcZyR8vfvSS95kSkrrS/9aHPavMkUZt7eHiRm3bctwTzj0xVy2RUt4kmEbkjad7EMf7q0k9yHuY0tpcOq7nL8MAOpwOMCoCs1wsjCOQyDlC2B2Pb070lo/8AgHTvFJ6FC01F/wC15YIoTHb4KsQSMn8+vYD+VdhE/wBisZrqUnzPutkjp/iB271z1pYPZ3HnuCplAIRucdQWPt16VvQ4nE4u1ed5F6LjBUZz+Ax161vQvHffpp6kYlxk01tp89ia5nZtThaW2iTzkHklXJ5wMA/XrVqLUbeKK8Es7xlhuRMH94o4Yg/XjH40t4HmhEcsY8yEr5aZ6jrgn3HWmXBfUbNpnRPJgjAgjH3yoPzMPoeBXoxWrf6f8A4dJJJr+v6/UNTu11O7ttKigaFJQXTZ1Z1HCn8Mkmi8uo0g8oxi3nK4ZGbA9Ac9iavmxOhQvdxQyzSqCqswHmMxwcEdMAf0rkNWTUdRt5XKjyWx5bfp+v6VpW5VH7+n/AChCNRqztFGLroKm4QxiNRliFJ49SCazQoFqhypZ16HquD0+p61oaiZIQiEl4449hb1A6n8Kz4FK2aDgPtJCr0xnpz69TXz07c11+X/AAD3YXUEWdIkYmKMoPKZCN/dVz2Hrnj8a04ZVtopDkCUEMQCeD/dPtSafE8NvzGDGf8AVOOxH8R9uoqxcojubZmEMtwDubqoH+yTyRx396UY7f5f8A5ZyUp67FW+kn8uaO0gE082Hk6koxPCg+p/rWjoVlcwXi20rJEHB82KXcuD746EUmnCWYwQKDGXmEqyk8E4xn8qrxzS6jftaI1zMFVslANxVTn8q6E72lr93p5dTOTcouGy6kerXbTvPbzQQMRhIyjn5Dn9R706yvzLBtvGidIEEYkQkb+etWoLFYNRCi1mkgil8wFVG7oPXt9aNMa2aRjGIIIZZicH0HQD3/pSUZSdkvw/4A5ThyWS2/r8kVJY57uLAjT7TE7gEk7gFAzkdNo9etVtJs4gUaSYNOyhwpJwR2z3ya2Us7v+0ikd4trEUKybcGM4GcZPOKi1CO2K20sMAgd2wZMnLEjp+NU78u2v/DCVX7Ke/b+vyNXTJvLmMEP2d9qnOx2yD3/KqusSpCrzKkTsoddzSMCNwwM47fzrNtVGn37S+bJ5rFswkDKgDr7/AEq7Ppz3ttcyxpKPPbaQP6/TPNCu/da69v8AgGXLGFS7ehlvZz6lHDPZWjTRiJULIONwGD3orV8O3kOiWDWVxOvmpKxOWwTz396KzVCDV3LX+vIJYrEwk4wjottz43k/1jfU11nw+jEurWUJZ0aa8iRGBwCScc/p+dcnJ/rG+prsvAwS6hlt/J81xG6LtJDRu2Nso7fLjH417+JdqZ8thleeh9D6VCq6fLbhSJI5N0qtk7COtdFa2cCut6vDDJ5JJHrXK+HZBN4ZQwO7TSJmbYf4lYD8iOteh20Ec1tJFA7bMEhSeen868uhHU9qpUcV5M3rJ1FurBSIX+7xye2fpVyA5gyc5BKKSefpWRZyz+Ta2SODaxHK8/d69a2oVZohGABs5P07mu2Gq3PMmuUsEKpQLkyN820ckjmmyxMjA8qCcbQOBUqrskJ+bBPyuDn86lba/wA0jZCnHXp71biZc1ijKvloylTljgnr+dY12gSVY2UOhbKr1wvp+dbd0zI6hWbaWOTn73uazLtt5Yx7hucNycenNc9RLubUmzzX4l+Gz4i8OtHC4XULMia1fp8y9h9RxXl+g6kNQs1uMbJVcpLEBlo3H3l56HvX0JfKHilEiqVJAH4EV8/eJrNvD/xPu7NBtsdXT7TEoPyrKOTj8B+tcFWClFrtr/mezhal7J/1fb8X+J1VvOghD7z8xGCvJHuParku4MoSTLKSMAY57isKynITGSYzgn0WtcOBK+5maRs98n61wJ23N+TllqW3ikKSSJIxiQAlQOOfSoYJFjs5HmLeSQAqFTt4/X0pVlxtgLFmI5UNk85/Oo9OV7hrhJ/M8tE2hc9hmtYyZrH4XzeRfsXMzAuiKXUbBztBPTHv9arC8mhNwm+NfJIJPQ+h/lUkQmton6nKndz0471Xjja4tblXO9m2uCONy+nPUVrJtrXz/UUbXbe2hrvfwy2iLFIPNxkYzg9Cc1majcSCby0ZWeRRzjvj9Mf5zVfIKqio8URIDMe3+yamm2BykUe6QrgOTnqOP8/zpSm3uXTpxpsNOvEVJERsOikPIBleO/NYMd88l0zW5J/e4bdxz6/1q3M3+gyxJGAXwAzckY4OMdqydPjMJOSR1VgOpqebQ76cIxUnbc7K1M8m1gVkKfekJOeegrWgvovtGBFF5pxs2A4B9vpXJzXb20MbKoWBv493JP8Ah7VPe3itaogUo33gckHqcYrWnOxxyw7m1fqddfJDdho3LG5cg+bkgjtgD/PapEkmjtxabkl2qrtL0ZQPUf3vSuQ068vbhFR53jGQquTycnmtyzvoo9ieYjA5ClWJbPTn29q7VWXYwqYeUFy72/r+kabXpMjWymOaMKx3MDx06/1rJvH/AHSwSlI5WZcIuTnPem31wVAlQrvX5fvdBxWOJRJMt2ys90MKHDck/wD6q58RW5tAp0ftf1cgv4WU7WAfksXYHDkdPyqO0gNzdYnYeXHkFB2YjrUV25Edy5GGJ2rtbGT/AEFWNPtXggmgliEjL/rSpIHTOf6VyW8jsm7Rtf8Ar+tC1LcSxW8bBAZBGWUKp3A7jyff0qzpmmf29qDzSyArAdpD/ezjOcAcr/WqlvdXFmsksmVJXKRqciM9N3rwKuXbW6RQ21tKiTwrteeA/eXJPf3NbwSi7yWmhjLmXux0v1/My9Dle71mPznVbeJ+OCA2OxrZmvo4XNza2SgwsNvz9V5zx1x0x9Kp2sa3umfZxbH7TLJxcu3f1qs0EL2d487bZIogFMfQMGAxn1xzmkml8CHKMZz19LfPyZrXYEitM3mNcSqrJGONueoPqKydMtPPmMLjyZEP+sb5mb6Y79a0vDUkk7JDJGmCoUODg49T71sta29t5kzM4Z2y6DgpnH3fSiEedf15GMqrp3p9R8URFpEwsw4RSSGHOR396ozrJqBXdukjGCVxgqSD19x1OKbfXjvBuDNFEhbiM8uuAOarW8klsmwxssisBnpkEda2uuhEISS5r6kGt3i2CwKscfmNnO1TjGeTz29Ks29zGbqyRZGVlPmLtGQy4zj6e1Z+q2v2q9S2ZJ0Kxeasx+7knG3P61ozQxW/lgRg7FAAhPUjqxz696yas7s1mocqit9b/wBehffWZbGWVJdPV/Mcyq5TllY8ZxRXPX18jTny4FAAxy7c/kaKXtn0l+H/AAC44GMkm1r8j5Qk/wBY31Ndd8NZ0t/EEPnM6xS5T5Rn5hgiuRk/1jfU1t+GJvK1KweN1SZLgYOOcHv+GK9+ur02j4yj8aZ9M+CGeHV9SsUQtb4VoSF55AyD+J616LZN+4BYnyz8oYL+f/6q8ztJ7pfEFxHAYxaypG+5T/EMZGfQg5P869J04ylI2LrlvlBOcY9T75rzcP2PYxEbO/f/ACNiBZA4HmZzICvHDfL0rRgbcquo2qeAMcfnVCGf7oZ080NtwB+v0q1G7rbpHFtOSQxUc9eK7ktDgkmzQQuVEe8+UCVLKMfU8/yqdkUqjF1zncCwxlulQiRGQqSAm85TH69KSUs5dGCbCMY6gnsPyqmZPcgcn58vnBPyFen/ANeqLo7Sl5W+Y9AF6Mf/AK1Wp5ioYnayg8cEn+VUbskxlUcenK8e+K5pm0EzMvCRbgxMAc84TgYxx7V458d9ONz4VttVthK15ps4cttwdpxnnt9K9ZklzCSACTgKW6ke3qK5vX7SLVdKvbMIgSdWUDnn5ev51zSfK1LsejQhf3ZbPT7/APLc8vsL1J7Zby1J8qfbINw7HkD2roLK582RmDERsPulcFR/+v8AyK878ESOmkvazODcWF28G3uQP8mu8sWMg3JIFxk/Nz9K82tBU5uJ6PxwjOW739epbjz5zMki/fOWA5z34Nau5I4MyABgoBJGMH3H9azomV5Xd3Tg7iQp69/wpz7X8wbgExufHIPcY/wpJg3zfEacc5jSUEq27IPy8cevvXN+IL+WxtIxATuLFiAccntz2rV0+6VrRVMbFSTuOOgHp71DrVrG6xkqrBCDtxwc+nv9atN7/wBdTSgoxnZr+tifT7kHSUWaXM3l+YVI7DBFULmQqvmRyEhjkAcHLD/Gmo63EqQq4VtpAHoOwPv61DpSNKrRuUXbIwOR82M8+30qJf1+JvCChdsFa8ltzFIgjEYyWA5amRqiW8k1xFuflVOOQPX8fWtiERlGjE/ynoSfTp+HrWberK1vOqxiQ5IG0/mKpJXRtTkm7LRFOyke+ZF+YRZB2AZx710NtaeY7sFkZQNu0DAXHY/41kaDZylHeeA5ONvOCvsD610NupE6mBD86Mrc8h/4efUUpct9DOtU1siO3gliuR5sBkDSDbtXlR3/AD9amEa3PnRosiSqf3jqQMHPH4AVCbw28k21nVc54OM46j8TVQXpu51YOiMOrL0b8PQdKptK7M7SfvF1gCY48GQpncQOn+etZ93MDMVt4282ZOcDjHQnH5VckmjghmDRCSR22ht3AyKhVP34lVFkJxnOe2M1PMgi+XUzvISKVVuE/dBgTGQTu/xrpIIJVjumMbqrkZjABwcetVZ2+x3FuIYPMuGVssTgK3b8q05draeinBlC5JU7cnuPqfXp9K0p2M61Ryafcx1jS+lkmMnlCLCy5PBx/MYqzFBDPF/o46yMqWwX5dvoTS2gsxDE75LyAksPlKjkE4qhdm5025lki8pEV8FQcA8cHHrVqemuxes3yp2tt+Qstz5VqIBCqiBiEAPqeT71Unt2uLzbyzbSSiDAA7Y9RUeo3Rums47CKJbmQhTgH5ie59M1q28E8MyRzNGHwU3A8c84/CsLt6r+tjTm9mk1o9zS0M25lQ3AdcjaAqg7SAODTtT1Hy7fNzGzMBubHQe49RVaOSawB+0JGIFkwW5AIx09fxrKumhu7SOIykTv8u9s5+v9K1jzQ92+v/DHNCkpT5pbFq31WO4094gzFBwpOCfYcfnSw3MtwjnzHaTaFVsY9sn3rJjtYLXzoGkDTleX6fMOg/DrmrV7fNPapK6KJmiQblPBI6nHbmm5cvU6lTV7RW5oyzTPa2tqUdfs7tIXABJOMYz3FWgqTFTEJBJkg9PToB61yTXUgchWyNo3Lk4zW1YXUgtQ7xxtv4YAk4Pt/OpUujFVoOKui02j2+on7RJdRQyHhlYkHI70UzffOFNtbPLHjG9cYP50Valp8N/vM+auvhnZeqPkiT/WN9TVzSpFS9tjIPlWUE469ulU5P8AWN9TVnTbdru6jhj+8x5+nevo525Xc+Jp/Ej608FedJ4ftJlLySoclTj5hnoPbFd1ojJ9gLxSSBEk5zjg+uPWuC+HsbR+E7OCSPBVNoXByDnP6jmu7tykFkqskbHOd23r6ZrzaGlj1anvGyFEru4dgd2A6jgfh1qxbM/IkY4PAPb2Ht6mqli2Ym6EKRyBwP8A61XYAIrUMm0yAkgYyc+xrqTucz00L0cr+WkilihfG7uRzz060PKGkdiHC9VUHge2fSmKf3A3LGcEMOO3+e1XDJCco4UAN90Lx/8Aqqm7GT06FJ0/efNvK5yRxk//AF6pXYYzEF3YnhsYBz78e3FaV2drALKhH3shenasy9LtM24qFLbSSucgVlNmkNWY10y4wGdGHHOD6cH/ABFY91E/mNt3BRJjPBzwOcevYfhW3fwReSzsRhDwDzjJHH5Vl3afcmQIyo4zhcHGMcf59a5J7P8Arud9Jq2h8+XdoNG+J/iLTDwlxieJGPy53D8+Ca6qwmYkjKhR1I9KzvivaR2XxM0DVCdkVxGYJCem4A9Pzp9rJsL4Cku5PHynP+PrXDi1qpLqv+AepR96Mk+9/vSf53OoWXZkBmOThSMdB6/0qDdKkty6kGJ4cBschs9x6fSqtk3mPJFlGwcg46ewH8quSBAnKKBgZwO3+f6VzKQJKLsGnSBQombKhfujuBUzyyNFcGJmx8qEEgrwc8+3pVOSKTzBx8qg4IGOexHp9aYoeAfu2KxsweQAck9v1p83n/WptGMW7ow7gzJrZkjAERH3AMEH1z6VvaXJ5Vk7FWRmYq3Qkg8HH9Kims0k+ZFG4bnKnIJzyR9f51e0YRsrLNEsaoQRxk8dP8/yqpSvsdFSUZRuuhT09Sl4luiN8p5diN3Xj8BXQSRRrM7SeY7ZzlCAc44B9vX29KbMsKyNdLExZhtPHH5df896NPhDzPKwL2wBEik5y2OPoaV7O5zTqc3vf1+Ys8jqq4WRotnzlSMcZ/T079ankmhitI5IYmGFfahPy7ueT7dc/jVPVb5LKBRDIJFchgWX5QRnAx6+hqrZXJuSyyFxkFx6A+ntTWnUaptpTexSkt7y5jkmuAYrNzyOCSenHsTmpNPtkhTIVvMC/L6Aev0Fb0skHlRpO/yoAyggg7u3Pr79vaorwQRln2+WFXcTjHA6ke39abkuhp9YcvdtuMZEEhnaKZTs3nGAeAMf4/5xVjTwJoTMd7NgY2EB+3I7Vly3816jJCHKSAozDOSPfPXiti1Bs9PbZAXBjBPy9gcZNQmnK1zGomlZ7l2OIyEHLoAjLyRjHH6D/OaydQmKafJIC5iSMlVyOT0Ax6d6L6+MSK8+VSRCmwjj6H/Gs1b8T3McqLvMUqvsLcEjtW3tElZDpUpfE0PgvZIYj9qaSSRU2AP3HUnFZOt6hJcIqSRF8AsSDlj2wP8APrW54jt2uJY7kSkIE8+4yMM3OOvft0rDs9PS6vW813Qg4dkzu9ev0o0i7t3R0UnC3tP6/r/Ms2CQ6hqkISOVLVQPLTcAwbHt7itqztwTGQ1w8+ThmIBHr7cU6zt1sokeJDFtz8ygKSD7U5rlYkJAcPt+VgOMe4rSdTnfM9P6RhKTlpHYdb3kMjJHNH5cTSFfLz827HUE8c+9cxAEbxLJbXFwTHEMjaMb1B4bB7npV60vriTUDHcxtHK0mQu3dnjkGpLh7OSee7jszGYzmOX+IA9BnuPas1Uv8RqoOm3FdRjqkZluLkTFXUupQrgL1AGagto98ETlCVZFJPTj2HbP+cVZs5YZQGkRnT5g4Zs72x6e3WtJry3uHV1R8qigyTnLgdOvenG09W9RynKL2Mp0Ee+FEYhl+XcR681at3WGIkB4lJweRnoRj60t1BE4Xc0aFAVBRT8w7de1QTcHym+Zgflf0yKzlOSehV1JWRr2LbrWPyAuwDH3sZ+tFYKXNrENk2XcHBIPH4e1FVGrZf1/kZSoav8Ar9T5bk/1jfU1r+FGaLW7O4QfNFKr59ADz/8ArrIk/wBY31NdV8NN3/CVWypzvypU4wehwc9q+lrO0GfE0leaTPqrSB51ogWT926g5Bx6V08ASQssinymIYEvznGP8muQ8LTrd2cJ2gEtgLjHQ9M+9dlbkrGMY5J25HH5dh7Vw0EuVHoT0LlsqxxuBwoYEHOMfhWgIISmxfvDPyA/eB9RVUISyEIuWYbB1HA/T+tX5CWhYlE3fcBHAx161vFW2MJPW4+NXaMGQMDvy3ORkDHP+NPMTRoux+2CDyCM9KlYYC7WOXbIYfj/AJwalYRkARsMA4wRjPtV8pnzFZ90pyyhASQeeRn0/wAaoXyyB2CLiPA4JxxWldNIGBDAMc4x0HvVV5pFcvIF+YjGPTioevUqDMJ0VjmPjI5wePx9azJY0EU7hyjMwZju57Y/z2/Ctto9sEhcKVJ2jb68flWNqAcozkDeCD0yM8DiueWn9ep3UpXZ438frXb4f0q/zl7O6GD1+XiqoKtdFlwQ53Bs5znv+NdV8UtOOpeBtVgXc0kUYkAxyCpB5NcD4WmF5oOnTdxCquxOPmHB/lXn4lXgn2f5nr4e3M/Nfin/AJNHRabA8Op3M+59roEKqfmyucHP1rZTMkMnmFWyuOT83qefT271m2JAldiAqDkEda0UDFXRV3ZGRx1A/lXFe7Co9bsdIXBn8tOcYyWxwR+o9qxLu+itZUjYLJJgYRjnIz6entWtd3TrBIFLcrkEj5Rxz/8Arrzq4u1uPE8e9WX5QgBOAfXFawjzXN6XuxvLyR6QkzCB2gAchc7xwOeqkdeOn+NLaSrA2+MjcWU7Qc59/wDD0rN0yeT7GwXJILDLDrnjNaNhG32PMir50ZyCBgn6n2qW3t/XU0aUU0xzvePdMwJ2Fdu3f19easwsyh0TAkkypIbHOPr1qlqN08Npu2MJSvReNx/+vUXhyJ7pt9ySkhBG3G5h74o1eoTXu8z0ItURnC+cruoIIw3QCqttfyiby4Hk2A7W56juD/nmuivrV2hH70HKgEle3ODVaLToIWSSEOrlTvZlz0/x9e1Vd2saRqwcLMkuX8uBpbxPkQg8t+XFU2N1qtqMK53KQpJ/hz+g9q6S5sTPFGXIdkAABXOCf4j/AEq1FarEECEGbHORgH0/D3qVFs5ViYxSstTM0vTjCgjBbAHyndyvA5z2rUTzoZIwruFaPCnf1JxUd9cyRxzi3XfIg7LjfwOD61BZ3NxHDGuoSBbho8hQAcE9Me2K2hyxMZc0lzMwtZW4vDEkELsVYx5L7Ru6kc9KTRtJaKyBLxmTfgorc7v6DFbKoZXIjMh+U7Q/zf596uW1r5XmtLKHQAEsIyAeOuOpp01fSx0SruMORGHr3mx2ACuHKR5Qk/dOTk4q5o8kbxrIwZ2K7XBYgM+M59jj9Kg1ITkhoWSRAnLFMjGaZqV/HZjl2kmPVBw2cd/eoT5RcrmlFeZqCKO4Plli0jYbcTu29se1Ur2IrKI4oAVWTBZmBwaTSEuniW5lmfJOMAcn3PrWrFGyRxxTjYyqQAFzuGf88VbXOrtf1oZyl7OVr3MtreG2nM43ea7ZaTzNoVu+D6+9Yd8YpGZGZwrDPDYx/gKl8WX72hjhhChS5+bbjI9cevtXMXWrTHU4bdbeRraUFjOMDYw9fUe1JRlJ7f1odlKLjFTl1L51KLTzslJHzYEa8kn6fzNKdTI2ORJDuAwZAwUj1APaqS6lJpFxe3MURaaWLZFKI9xj7nIPJz7VgjWtc1e3W1vPNmgVdinptJ9j/wDqrWMIuN2xuo41LOOh6HYv9phQPuZT1IbkAd6vCBnaRY03hWB2uc549feua8PGS1jVJJJMxBQZSMFiPWushuGZ3kl80KW4wNvGP1rklGzIqc0dUZ00EayElEQnkrtDY/GirC3iB5BG6FQ56HH6UVi7XE6jWjPk+RG8xvlPU9q6bwFBcPqyNbQq8qHjccdfX2oor6zEu1NnxVD+Ij6k0aw+yokMTRsrIrKqHk8AkZ+ua6zSTI0CSSAo0nO12zjFFFclJctrHfOTcVc3LVlVRhVUhhjPcelXRE5QnAZT93n7o/rRRXVFX1ORuxbt98cbfOuS2OM5H69KsHcFGY2BDYPzDn2x6UUVS2M2VZhsVxsjJ7AnIx/ntVGVWWRvMKgAA+q5/u/QUUUp6GkGZtzjYSpT+8EHBI+v9KyL7cxfJjGx8gjI4wORRRXFUlp9/wCp20jm9WjS6gvIZFVhKhXjI428D39cV4T4D/0fSr3T33ebaXjgYU5AOBn8cGiiuSb5oT+X5nq0tJw9X+V/0R2dtP5DoWXAyMgdPpnuRW3Ey7i0MfmIRtByeKKK4OlzqqQVriPAZlZeNxJZs5I6df8A61ZE+kQvF5m1t0bAbuhPPP5daKKXNb+vUKU2tF5GvbRIttsfIZhtG0cnngn6/pUhaOFTHNIyOML8mRn1/LtRRRfU1hHmbTMTXrloWjhCklgSGU5GB6+/rSWuoTvLbxxAtGf+Wq5GD/jRRW32bnWknGx11qCZlFwysF5UYPX19sfrWlPCs3zwuilVI27SuMd+f1oopQfRnlVdGmVLy+itIFFxITcSkYESHP1H9PWrMMvmxF4F+YrsyQcZ7D8qKKibV0rDnTUYRl1Y2SCJpAhnbzBy20E7UwMgjsSf0quqpdSs4jOQvlhyDjtzRRW07cyjYfLZXuaUUYNsNjEYjbdkEHPbn+tVroMCpE5KMoABBJPHJ4754/xooq2+WF12M4LVla6Ywq32aVTjv0Of896yystw8GICZkyS5XBI9/f+lFFYSnrZdbHTH3Y3Ol05hHbAu7GUDBVVJwe5z6elS4LpAqAiTG5VbJAHYZ/rRRXRCV0o/wBbo4pxtJs5+9sknDPOgLA5+ZSTx1OcdSaxJrKEyKjpukC55Bxn1z6UUVhztaf10PSoN2f9djFv7i48tY4LVJpFbEjSHayr6j1+lORHWISAOWOOCM/X6CiitJWUVodjjaVkbthbbMiTc6lN3APPpmrlxfpFGyXCF4YxjIByD3zRRWL1OaMfaS94zrYwTxmSBJQrHJw2ATRRRWEtG0KaXMz/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lippincott Williams &amp; Wilkins. Copyright &copy;2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8964=[""].join("\n");
var outline_f8_48_8964=null;
var title_f8_48_8965="Waveforms Swan Ganz tip";
var content_f8_48_8965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 578px\">",
"   <div class=\"ttl\">",
"    Waveforms by location of the pulmonary artery (PA) catheter tip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 558px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tracings obtained in the right atrium or pulmonary capillary wedge position share similar morphology. The transition from the right ventricle to the pulmonary artery tracing can be identified by the increase in diastolic pressure and the presence of a dicrotic notch. The diastolic \"step-up\" results from the transducer crossing the pulmonic valve; the dicrotic notch reflects closing of the pulmonic valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Marino Pl. The ICU Book, Philadelphia, Lea and Feliger, 1991, p. 103.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8965=[""].join("\n");
var outline_f8_48_8965=null;
var title_f8_48_8966="Felodipine: Pediatric drug information";
var content_f8_48_8966=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Felodipine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"    see \"Felodipine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1221?source=see_link\">",
"    see \"Felodipine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Plendil&reg;;",
"     </li>",
"     <li>",
"      Renedil&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Felodipine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1013431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker, Dihydropyridine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1013463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"      see \"Felodipine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge; 6 years and Adolescents:",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 2.5 mg once daily; may increase as needed at 2-week intervals to a maximum daily dose: 10 mg/",
"     <b>",
"      day",
"     </b>",
"     (NHLBI, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 2.5-10 mg once daily; increase by 5 mg at 2-week intervals, as needed, to a maximum of 20 mg/day; usual dose range (JNC 7): 2.5-20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for renal impairment:",
"     </b>",
"     Adults: Usually not required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for hepatic impairment:",
"     </b>",
"     Adults: Initial dose: 2.5 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Clearance is reduced to ~60% of normal in patients with hepatic disease; monitor closely",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1013468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Must be swallowed whole; do not crush or chew; should be taken either without food or with a light meal. Do not administer with grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F14851058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1013432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension alone or in combination with other antihypertensives (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F170402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Plendil&reg; may be confused with Isordil&reg;, pindolol, Pletal&reg;, PriLOSEC&reg;, Prinivil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F170400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Angina, angioedema, anxiety, arrhythmia, CHF, CVA, decreased libido, depression, dizziness, gingival hyperplasia, dyspnea, dysuria, gynecomastia, hypotension, impotence, insomnia, irritability, leukocytoclastic vasculitis, MI, nervousness, paresthesia, somnolence, syncope, urticaria, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1013437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to felodipine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14851057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Use with caution in patients with hepatic impairment; clearance is reduced by ~60% and  requires lower initial dose. Use with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia. Use with caution in patients with heart failure; safety and efficacy have not been established. Use with caution in patients with hypertrophic cardiomyopathy (HCM) and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition. Use with caution in patients taking CYP3A4 inhibitors; may result in increased felodipine concentrations; monitor for adverse effects/toxicity and consider dose adjustments. May cause mild gingival hyperplasia; incidence and severity may be decreased with good oral hygiene.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1013438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic hypotension may occur with use; syncope may rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers; reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease especially in the absence of concurrent beta-blockade. May cause peripheral edema; usually occurs within 2-3 weeks of starting therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F1013449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8/9 (weak), 2D6 (weak), 3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Felodipine. Management: Monitor hemodynamic response to felodipine closely in patients who consume grapefruit juice.  Felodipine dose adjustment and/or modification of grapefruit juice ingestion may be needed. Felodipine Canadian labeling recommends avoiding grapefruit juice.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Felodipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1013452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Meals high in fat or carbohydrates can increase peak felodipine serum concentrations by up to 60%. Grapefruit juice may significantly increase the oral bioavailability of felodipine; avoid concurrent use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F170335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14851170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, peripheral edema, liver enzymes",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1013453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium ions from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization; produces a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F14851059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Antihypertensive: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Antihypertensive: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1013455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution:  V",
"     <sub>",
"      d",
"     </sub>",
"     : 10 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; CYP3A4 substrate (major); extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 20%; extensive first-pass metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 11-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2.5-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (70% as metabolites); feces 10%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1013472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1221?source=see_link\">",
"      see \"Felodipine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol and grapefruit juice; rise slowly from prolonged sitting or lying position. Swallow tablet whole; do not crush or chew. May cause headache, constipation, or swelling of ankles. Report irregular heartbeat, chest pain or palpitations, persistent headache, severe constipation, peripheral swelling, weight gain, dyspnea, or respiratory changes. Maintain good oral hygiene.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, &ldquo;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,&rdquo; Clinical Practice Guidelines, 2011, National Institutes of Health. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8966/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86263 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-4F267068D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8966=[""].join("\n");
var outline_f8_48_8966=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170350\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013431\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013463\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170324\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170311\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013468\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851058\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013432\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170402\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170400\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013437\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851057\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013438\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013449\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170320\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013452\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170321\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170335\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851170\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013453\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14851059\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013455\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013472\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86263\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86263|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=related_link\">",
"      Felodipine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1221?source=related_link\">",
"      Felodipine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_48_8967="Travel advice";
var content_f8_48_8967=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Travel advice",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/48/8967/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/48/8967/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/48/8967/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/48/8967/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/48/8967/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/48/8967/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/48/8967/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/48/8967/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical advice for travelers should include evaluation of the risk for adverse outcomes depending on the traveler's medical conditions, the itinerary, anticipated activities, and potential exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/1\">",
"     1",
"    </a>",
"    ]. Risks of illness associated with travel include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Development of illness while in transit [",
"      <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Exposure to infections endemic to areas visited",
"     </li>",
"     <li>",
"      Environmental exposures associated with travel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pretravel evaluation should provide advice about the risks for vaccine preventable infections, the appropriate immunizations, and prophylaxis against travelers&rsquo; diarrhea and malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/3\">",
"     3",
"    </a>",
"    ]. It should also include advice about behavioral precautions and environmental exposures.",
"   </p>",
"   <p>",
"    Fewer than half of travelers to high risk regions seek travel advice, and many clinicians are not aware of the most appropriate advice regarding preventive measures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, travelers returning to their country of origin to visit friends and relatives are less likely to seek advice since they do not realize they are at risk for illness associated with travel [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, preventable systemic illnesses such as malaria and typhoid fever occur more commonly in this risk group than among other travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to advice for travelers will be reviewed here. Further information can also be obtained at the Centers for Disease Control and Prevention (CDC) web site (",
"    <a class=\"external\" href=\"file://www.cdc.gov/travel\">",
"     www.cdc.gov/travel",
"    </a>",
"    ). This site includes an online version of Health Information for International Travel and updates on travel-related infections [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/3\">",
"     3",
"    </a>",
"    ]. The World Health Organization (WHO) operates a similar site:",
"    <a class=\"external\" href=\"file://www.who.int/ith\">",
"     www.who.int/ith",
"    </a>",
"    . Guidelines for the practice of travel medicine have been issued by the Infectious Diseases Society of America in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to travel advice for immunocompromised hosts are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13081?source=see_link\">",
"     \"Travel advice for immunocompromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRAVEL RELATED INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travel associated infections may be acquired via enteral, respiratory, vector-borne,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sexual exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Among more than 42,000 ill returned travelers seen between 2007 and 2011 in the GeoSentinel surveillance network, the most common syndromic diagnoses were gastrointestinal, febrile, and dermatologic illnesses (34, 23, and 19 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/11\">",
"     11",
"    </a>",
"    ]. Asia and sub-Saharan Africa were the most common regions where illnesses were acquired (32 and 25 percent). Approximately 40 percent of ill travelers reported pretravel medical visits. Travelers visiting friends and relatives in their country of origin had a disproportionately high burden of serious febrile illness and very low rate of advice prior to travel.",
"   </p>",
"   <p>",
"    In addition to variability of health risks according to destination, travel duration, type of travel, activities undertaken, specific traveller characteristics (including age and gender) and other factors influence the chances of presenting for healthcare with various infections. For example, women are proportionately more likely than men to present after travel with diarrhea, upper respiratory tract infections, urinary tract infections or adverse reactions to medication, whereas they are proportionately less likely to have vector-borne diseases or sexually transmitted infections [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRETRAVEL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical consultation should be obtained at least one month before travel to allow time for thorough evaluation and for immunizations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .) A general medical history should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pertinent underlying medical conditions (including immune compromise due to transplantation or human immunodeficiency virus infection) and current medications. As an example, splenectomy predisposes to more severe infections with malaria, babesiosis, and encapsulated bacteria, including Neisseria meningitidis.",
"     </li>",
"     <li>",
"      History of allergies to antimicrobial agents or to components of vaccines (eggs, gelatin)",
"     </li>",
"     <li>",
"      Whether the patient is pregnant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Understanding the itinerary, duration and purpose of a trip can help to estimate the risks of exposure to endemic diseases. Stays at major resorts and first-class hotels are associated with less risk than visits to less established facilities or rural dwellings or encampments.",
"   </p>",
"   <p>",
"    Patients should take sufficient supplies of current medications; equivalent drugs may not be available in travel destinations. Medications required for daily use should be carried and not left in baggage that might become lost.",
"   </p>",
"   <p>",
"    Patients should also consider travelers insurance, including evacuation insurance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TRAVEL ADVICE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22623984\">",
"    <span class=\"h2\">",
"     Vaccinations and prophylaxis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22623457\">",
"    <span class=\"h3\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization for travelers can be divided into three categories: routine prevention, required for travel, and recommended based on the risk of exposure to vaccine preventable diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/7\">",
"     7",
"    </a>",
"    ]. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22623488\">",
"    <span class=\"h3\">",
"     Malaria prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to malaria prevention include mosquito avoidance and chemoprophylaxis. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22623429\">",
"    <span class=\"h3\">",
"     Travelers' diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk of travelers&rsquo; diarrhea should be reviewed and prophylaxis offered if indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=see_link&amp;anchor=H23#H23\">",
"     \"Travelers' diarrhea\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22624013\">",
"    <span class=\"h2\">",
"     Behavioral precautions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22624029\">",
"    <span class=\"h3\">",
"     Food and water",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is prudent to be careful of food and water in areas where sanitation and personal hygiene may be poor. Infections transmissible by contaminated food and water include travelers&rsquo; diarrhea and hepatitis A and E [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/15\">",
"     15",
"    </a>",
"    ]. Transmission of parasitic infections can also occur.",
"   </p>",
"   <p>",
"    In such circumstances, travelers should avoid consuming tap water, ice made from tap water, and raw foods rinsed with tap water. Chlorination kills most bacterial and viral pathogens, but protozoal cysts of Giardia lamblia and Entamoeba histolytica and oocysts of Cryptosporidium may survive.",
"   </p>",
"   <p>",
"    Boiled, treated or bottled water may be consumed. Carbonated beverages, beer, wine, and drinks made with boiled water are safe. Produce that is peeled by the traveler may be eaten. Unpasteurized dairy products and undercooked fish or meat should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550184342\">",
"    <span class=\"h3\">",
"     Vector avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers to areas with malaria, dengue, chikungunya, and other vector-borne diseases should receive instructions regarding methods to prevent bites from mosquitoes. These measures are also generally effective for reducing risks of bites from sandflies, ticks and other insects. Measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoiding outdoor exposure during mosquito feeding time (for malaria, this is between dusk and dawn)",
"     </li>",
"     <li>",
"      Wearing clothing that reduces the amount of exposed skin",
"     </li>",
"     <li>",
"      Using an insect repellant",
"     </li>",
"     <li>",
"      Treating fabrics (including clothes) with insecticides",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors and details of appropriate repellants and insecticides are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=see_link\">",
"     \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550184353\">",
"    <span class=\"h3\">",
"     Respiratory infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory infections such as influenza and other respiratory viruses are common in travelers. The importance of good hand hygiene should be emphasized, and appropriate vaccinations considered. Tuberculosis is also an important respiratory pathogen among travelers to endemic areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Swimming and beaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Swimming in fresh water should be avoided in areas where schistosomiasis is prevalent. Even short exposures to infested water during rafting or swimming are sufficient for transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Swimming in chlorinated or salt water is safe. Rafting and other water related activities, including exposure to flood waters, can also result in exposure to leptospirosis.",
"   </p>",
"   <p>",
"    Travelers also should be cautioned about the risks of walking barefoot or in loose-fitting footwear on beaches, on soil, or in water that may be contaminated with human or canine feces. Such exposure may lead to contact with hookworm or strongyloides larvae. Acquisition of the larvae can cause cutaneous larva migrans, hookworm, or strongyloidiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36229?source=see_link\">",
"     \"Cutaneous larva migrans (creeping eruption)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42437?source=see_link\">",
"     \"Hookworm infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"     \"Strongyloidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Travelers should also wear sunglasses and sunblocking agents with ultraviolet A and B protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H545876359\">",
"    <span class=\"h3\">",
"     Animal avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers should be warned against approaching animals and should be advised regarding potential risks from animal bites and scratches [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rabies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22624051\">",
"    <span class=\"h3\">",
"     Traffic accidents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accidents, especially motor vehicle accidents, account for about one quarter of deaths among Americans abroad [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/20\">",
"     20",
"    </a>",
"    ]. Travelers should be reminded to diminish risks by avoiding driving at night, using seat belts, becoming familiar with local driving conditions, and avoiding alcohol consumption while driving.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Sexually transmitted diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers should be cautioned about sexual contacts, especially in areas with high prevalence of HIV, hepatitis B, and other STIs, and should be advised to use condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TRANSPORTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22623759\">",
"    <span class=\"h2\">",
"     Air travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged immobilization during flight may cause venous thrombosis in individuals with preexisting thrombotic or venous disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H38#H38\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Extended travel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13737?source=see_link&amp;anchor=H8#H8\">",
"     \"Patient assessment for air travel\", section on 'Deep vein thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Jet aircraft are not pressurized to sea level, so passengers are exposed to high-altitude environments, resulting in diminished arterial oxygen tension (PaO2) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. For patients impaired cardiopulmonary function or other health problems (eg, sickle cell disease), supplemental oxygen may be needed (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In travelers with upper respiratory tract infections, differential air pressures between blocked eustachian tubes or sinuses and the cabin may develop on ascent or descent and impair hearing or cause pain in the ears or sinuses. Symptoms can be relieved by the use of decongestants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"     \"Ear barotrauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Jet lag may result when travel extends over several time zones. Issues related to the prevention and treatment of jet lag are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=see_link\">",
"     \"Jet lag\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3271664\">",
"    <span class=\"h2\">",
"     Cruise ships",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cruise ships that dock at ports in the United States are inspected for sanitation by CDC officials to minimize the potential for gastrointestinal disease outbreaks on board. Travelers may obtain information on whether specific cruise ships meet sanitation standards from travel agents, state health departments, or the CDC (",
"    <a class=\"external\" href=\"file://www.cdc.gov/travel\">",
"     www.cdc.gov/travel",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SPECIFIC MEDICAL CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions warrant special consideration before travel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air travel in pregnancy is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H28#H28\">",
"     \"Initial prenatal assessment and patient education\", section on 'Airline travel'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Issues related to pretravel immunizations in pregnancy are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Careful attention to the need for malaria prophylaxis is important since malaria infection can be a life threatening infection for both mother and fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention of malaria infection in travelers\", section on 'Pregnant travelers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For presumptive self-treatment of travelers&rsquo; diarrhea, fluoroquinolones are contraindicated in pregnancy. A third generation cephalosporin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is an acceptable alternative choice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several issues related to international travel by HIV infected patients to consider. If possible, competent medical facilities should be identified in destination countries, and all medications should be carried with the traveler. Some countries will not allow entry to individuals with HIV or those found to be carrying antiretroviral medications; consular offices for countries should be checked prior to travel. Issues related to travel immunizations for HIV patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to routine causes of opportunistic infection, infectious risks related to travel include parasitic opportunistic infections (eg, Cyclospora, cryptosporidiosis, Isospora belli, and visceral leishmaniasis) and fungal infections (eg, cryptococcosis and histoplasmosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31493?source=see_link\">",
"     \"Cyclospora infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30405?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21161?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations and diagnosis of visceral leishmaniasis\", section on 'HIV-VL coinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;East-west travel across times zones often requires adjustments in insulin dosing. Travelers need to carry their syringes, medications, and snacks in carry-on bags.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL EXPOSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers may plan specific activities during travel that raise additional issues for evaluation and counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Diving",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scuba divers should wait 12 to 48 hours before boarding a commercial aircraft to avoid developing decompression sickness, commonly known as the bends [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/28\">",
"     28",
"    </a>",
"    ]. There are a number of issues that merit consideration for travelers planning to engage in underwater diving; these are discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link\">",
"     \"Complications of scuba diving\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     High altitude",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific pretravel advice and medication related to altitude illnesses, including acute mountain sickness, high-altitude pulmonary edema, and high-altitude cerebral edema, should be provided for travelers to high altitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cardiac disease should be evaluated and counseled as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link\">",
"     \"High altitude, air travel, and heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Wilderness travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those planning travel in outlying areas away from medical access and who are subject to potential environmental and exercise related stresses, specific advice and planning should be offered based upon the traveler's health and planned activities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8967/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"       \"Patient information: Staying healthy when you travel (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=see_link\">",
"       \"Patient information: Vaccines for travel (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/3/20530?source=see_link\">",
"       \"Patient information: Travelers&rsquo; diarrhea (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       \"Patient information: General travel advice (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19654361\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risks of illness associated with travel include exposure to endemic infections, development of illness while in transit, and environmental exposures associated with travel. Medical advice for travelers should include evaluation of the risk for adverse outcomes depending on the traveler's medical conditions, the itinerary, anticipated activities, and potential exposures. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pretravel evaluation should include underlying medical conditions, current medications, and history of allergy to antimicrobial agents or vaccine components. Issues related to specific conditions including pregnancy, HIV infection, and diabetes warrant special consideration. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pretravel evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Specific medical conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pretravel evaluation should provide advice about the risks for vaccine preventable infections, appropriate immunizations, and prevention of travelers&rsquo; diarrhea and malaria (if warranted). It should also include behavioral precautions including issues related to food and water in areas with poor sanitation, caution regarding swimming and beaches in areas with high risk for parasitic infection, measures to reduce risk of traffic accidents, and caution regarding sexually transmitted infections. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Travel advice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Air travel is associated with risks including venous thrombosis, diminished oxygen tension, changes in cabin pressure affecting ears or sinuses, and jet lag. Cruise ship travel has been associated with gastrointestinal disease outbreaks. Environmental exposures warranting additional counseling include diving and high altitude travel (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Transportation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Environmental exposures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/1\">",
"      Advice for travelers. Treat Guidel Med Lett 2004; 2:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/2\">",
"      Mangili A, Gendreau MA. Transmission of infectious diseases during commercial air travel. Lancet 2005; 365:989.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Health information for international travel 2011-2012. DHHS, Atlanta, GA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/4\">",
"      Hill DR. The burden of illness in international travelers. N Engl J Med 2006; 354:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/5\">",
"      Bacaner N, Stauffer B, Boulware DR, et al. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA 2004; 291:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/6\">",
"      Leder K, Tong S, Weld L, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 2006; 43:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/7\">",
"      Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/8\">",
"      Steffen R, Ericsson CD. Special section:travel medicine. Clin Infect Dis 2000; 30:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/9\">",
"      LaRocque RC, Rao SR, Lee J, et al. Global TravEpiNet: a national consortium of clinics providing care to international travelers--analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. Clin Infect Dis 2012; 54:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/10\">",
"      Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/11\">",
"      Leder K, Torresi J, Libman MD, et al. GeoSentinel Surveillance of Illness in Returned Travelers, 2007&ndash;2011. Ann Intern Med 2013; 6:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/12\">",
"      Schlagenhauf P, Chen LH, Wilson ME, et al. Sex and gender differences in travel-associated disease. Clin Infect Dis 2010; 50:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/13\">",
"      Hill DR, Beeching NJ. Travelers' diarrhea. Curr Opin Infect Dis 2010; 23:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/14\">",
"      Steffen R. Epidemiology of traveler's diarrhea. Clin Infect Dis 2005; 41 Suppl 8:S536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/15\">",
"      Langer BC, Fr&ouml;sner GG. Relative importance of the enterically transmitted human hepatitis viruses type A and E as a cause of foreign travel associated hepatitis. Arch Virol Suppl 1996; 11:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/16\">",
"      Istre GR, Fontaine RE, Tarr J, Hopkins RS. Acute schistosomiasis among Americans rafting the Omo River, Ethiopia. JAMA 1984; 251:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/17\">",
"      Meltzer E, Artom G, Marva E, et al. Schistosomiasis among travelers: new aspects of an old disease. Emerg Infect Dis 2006; 12:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/18\">",
"      Gautret P, Adehossi E, Soula G, et al. Rabies exposure in international travelers: do we miss the target? Int J Infect Dis 2010; 14:e243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/19\">",
"      Piyaphanee W, Shantavasinkul P, Phumratanaprapin W, et al. Rabies exposure risk among foreign backpackers in Southeast Asia. Am J Trop Med Hyg 2010; 82:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/20\">",
"      Hargarten SW, Baker TD, Guptill K. Overseas fatalities of United States citizen travelers: an analysis of deaths related to international travel. Ann Emerg Med 1991; 20:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/21\">",
"      Ward BJ, Plourde P. Travel and sexually transmitted infections. J Travel Med 2006; 13:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/22\">",
"      Hynes NA. Sexually Transmitted Diseases in Travelers. Curr Infect Dis Rep 2005; 7:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/23\">",
"      Matteelli A, Schlagenhauf P, Carvalho AC, et al. Travel-associated sexually transmitted infections: an observational cross-sectional study of the GeoSentinel surveillance database. Lancet Infect Dis 2013; 13:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/24\">",
"      Silverman D, Gendreau M. Medical issues associated with commercial flights. Lancet 2009; 373:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/25\">",
"      Mohr LC. Hypoxia during air travel in adults with pulmonary disease. Am J Med Sci 2008; 335:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/26\">",
"      Steketee RW, Wirima JJ, Slutsker L, et al. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 1996; 55:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/27\">",
"      Milner DA Jr, Montgomery J, Seydel KB, Rogerson SJ. Severe malaria in children and pregnancy: an update and perspective. Trends Parasitol 2008; 24:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/28\">",
"      Sheffield PJ. Flying after diving guidelines: a review. Aviat Space Environ Med 1990; 61:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/29\">",
"      Melamed Y, Shupak A, Bitterman H. Medical problems associated with underwater diving. N Engl J Med 1992; 326:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/30\">",
"      Zafren K, Honigman B. High-altitude medicine. Emerg Med Clin North Am 1997; 15:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8967/abstract/31\">",
"      Backer H. Medical limitations to wilderness travel. Emerg Med Clin North Am 1997; 15:17.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3898 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8967=[""].join("\n");
var outline_f8_48_8967=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19654361\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRAVEL RELATED INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRETRAVEL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TRAVEL ADVICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22623984\">",
"      Vaccinations and prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22623457\">",
"      - Immunizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22623488\">",
"      - Malaria prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22623429\">",
"      - Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22624013\">",
"      Behavioral precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22624029\">",
"      - Food and water",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H550184342\">",
"      - Vector avoidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H550184353\">",
"      - Respiratory infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Swimming and beaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H545876359\">",
"      - Animal avoidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22624051\">",
"      - Traffic accidents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Sexually transmitted diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TRANSPORTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22623759\">",
"      Air travel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3271664\">",
"      Cruise ships",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SPECIFIC MEDICAL CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ENVIRONMENTAL EXPOSURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Diving",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      High altitude",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Wilderness travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19654361\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=related_link\">",
"      Clinical manifestations and diagnosis of rabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21161?source=related_link\">",
"      Clinical manifestations and diagnosis of visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36229?source=related_link\">",
"      Cutaneous larva migrans (creeping eruption)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31493?source=related_link\">",
"      Cyclospora infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=related_link\">",
"      Ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30405?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=related_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=related_link\">",
"      High altitude, air travel, and heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42437?source=related_link\">",
"      Hookworm infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=related_link\">",
"      Jet lag",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13737?source=related_link\">",
"      Patient assessment for air travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/3/20530?source=related_link\">",
"      Patient information: Travelers&rsquo; diarrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=related_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=related_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13081?source=related_link\">",
"      Travel advice for immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=related_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_48_8968="Lichenoid drug eruption 1";
var content_f8_48_8968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83767%7EDERM%2F83768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83767%7EDERM%2F83768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lichenoid drug eruption (drug-induced lichen planus)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this patient with a lichenoid drug eruption, flat erythematous papules are typically distributed on the trunk and upper extremities. Grouped and confluent lesions also can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lichenoid drug eruption (drug-induced lichen planus)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flat erythematous/violaceous papules on the shoulder and upper arm of a patient with lichenoid drug eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8968=[""].join("\n");
var outline_f8_48_8968=null;
var title_f8_48_8969="Hydrocortisone (systemic): Drug information";
var content_f8_48_8969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocortisone (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/36/35398?source=see_link\">",
"    see \"Hydrocortisone (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/46/22249?source=see_link\">",
"    see \"Hydrocortisone (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8116174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A-Hydrocort&reg;;",
"     </li>",
"     <li>",
"      Cortef&reg;;",
"     </li>",
"     <li>",
"      Solu-CORTEF&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8116175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cortef&reg;;",
"     </li>",
"     <li>",
"      Solu-Cortef&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8116204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8116314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be based on severity of disease and patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adrenal insufficiency (acute):",
"     </b>",
"     I.M., I.V.:  100 mg I.V. bolus, then 300 mg/day in divided doses every 8 hours or as a continuous infusion for 48 hours. Once patient is stable change to oral, 50 mg every 8 hours for 6 doses, then taper to 30-50 mg/day in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adrenal insufficiency (chronic), physiologic replacement (unlabeled dosing):",
"     </b>",
"     Oral: 15-25 mg/day in 2-3 divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     Studies suggest administering one-half to two-thirds of the daily dose in the morning in order to mimic the physiological cortisol secretion pattern. If the twice-daily regimen is utilized, the second dose should be administered 6-8 hours following the first dose (Arlt, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory or immunosuppressive:",
"     </b>",
"     Oral, I.M., I.V.:  15-240 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Congenital adrenal hyperplasia (unlabeled dosing):",
"     </b>",
"     Oral: 15-25 mg/day in 2-3 divided doses (Speiser, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Status asthmaticus:",
"     </b>",
"     I.V.:  1-2 mg/kg/dose every 6 hours for 24 hours, then maintenance of 0.5-1 mg/kg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stress dosing (surgery) in patients known to be adrenally-suppressed or on chronic systemic steroids:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Minor stress (ie, inguinal herniorrhaphy):",
"     </i>",
"     25 mg/day for 1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Moderate stress (ie, joint replacement, cholecystectomy):",
"     </i>",
"     50-75 mg/day (25 mg every 8-12 hours) for 1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Major stress (pancreatoduodenectomy, esophagogastrectomy, cardiac surgery):",
"     </i>",
"     100-150 mg/day (50 mg every 8-12 hours) for 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Septic shock (unlabeled use):",
"     </b>",
"     I.V.:  50 mg every 6 hours (Annane, 2002; Marik, 2008); not to exceed 300 mg/day (Dellinger, 2008). Practice guidelines also recommend alternative dosing of 100 mg bolus, followed by continuous infusion of 10 mg/hour (240 mg/day). Taper slowly (for total of 11 days) and do not stop abruptly.",
"     <b>",
"      Note:",
"     </b>",
"     Fludrocortisone is optional with use of hydrocortisone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyroid storm (unlabeled use):",
"     </b>",
"     I.V.: 300 mg loading dose,  followed by 100 mg every 8 hours (Bahn, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8116312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/46/22249?source=see_link\">",
"      see \"Hydrocortisone (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be based on severity of disease and patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory or immunosuppressive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Infants and Children:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 2.5-10 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     75-300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 1-5 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     30-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adolescents:",
"     </i>",
"     Oral, I.M., I.V.: 15-240 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Congenital adrenal hyperplasia (unlabeled dosing):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Doses must be individualized by monitoring growth, bone age, and hormonal levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 10-15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 3 divided doses; higher initial doses may be required to achieve initial target hormone serum concentrations in infancy (Speiser, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Physiologic replacement:",
"     </b>",
"     Children: Oral: 8-10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 8 hours; up to 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in some patients (Ahmet, 2011; Gupta, 2008; Maguire, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Status asthmaticus:",
"     </b>",
"     Children: I.V.: 1-2 mg/kg/dose every 6 hours for 24 hours, then maintenance of 0.5-1 mg/kg every 6 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Septic shock (unlabeled use):",
"     </b>",
"     Children: I.V.: Initial: 1-2 mg/kg/day (intermittent or as continuous infusion); may titrate up to 50 mg/kg/day for shock reversal (Brierley, 2009); alternative dosing suggests 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (Dellinger, 2008).",
"     <b>",
"      Note:",
"     </b>",
"     Use recommended only in catecholamine-resistant shock and suspected or proven adrenal insufficiency.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8116315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8116380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium succinate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Hydrocort&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-CORTEF&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium succinate [strength expressed as base, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-CORTEF&reg;: 100 mg, 250 mg, 500 mg, 1000 mg [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as base: 5 mg, 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortef&reg;: 5 mg, 10 mg, 20 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8116180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8116346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food or milk to decrease GI upset.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Hydrocortisone sodium succinate may be administered by I.M. or I.V. routes. Dermal and/or subdermal skin depression may occur at the site of injection. Avoid injection into deltoid muscle (high incidence of subcutaneous atrophy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. bolus: Administer over 30 seconds or over 10 minutes for doses &ge;500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. intermittent infusion: Administer over 20-30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8116281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hydrocortisone sodium succinate:",
"     </b>",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, fat emulsion 10%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, acyclovir, allopurinol, amifostine, aminophylline, amphotericin B cholesteryl sulfate complex, ampicillin, amsacrine, anidulafungin, argatroban, atracurium, atropine, aztreonam, betamethasone sodium phosphate, bivalirudin, calcium gluconate, caspofungin, cefepime, chlorpromazine, cisatracurium, cladribine, cyanocobalamin, cytarabine, dexamethasone sodium phosphate, dexmedetomidine, digoxin, diphenhydramine, docetaxel, dopamine, doripenem, doxorubicin liposome, droperidol, droperidol and fentanyl, edrophonium, enalaprilat, epinephrine, esmolol, estrogens (conjugated), ethacrynate sodium, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fludarabine, fluorouracil, foscarnet, furosemide, gallium nitrate, gemcitabine, gold sodium thiosulfate, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydralazine, inamrinone, insulin (regular), isoproterenol, kanamycin, lidocaine, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, methylergonovine, minocycline, morphine, neostigmine, nicardipine, norepinephrine, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, pancuronium, penicillin G potassium, pentazocine, phytonadione, piperacillin/tazobactam, procainamide, prochlorperazine edisylate, propofol, propranolol, pyridostigmine, remifentanil, scopolamine, sodium bicarbonate, succinylcholine, tacrolimus, telavancin, teniposide, theophylline, thiotepa, trimethobenzamide, vecuronium, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ciprofloxacin, diazepam, idarubicin, midazolam, phenytoin, sargramostim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Antithymocyte globulin (rabbit), diltiazem, methylprednisolone sodium succinate, promethazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate, iohexol, iopamidol, iothalamate meglumine 60%, ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%, methotrexate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, oxytocin, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cytarabine, magnesium sulfate, thiopental.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8116215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of adrenocortical insufficiency; anti-inflammatory or immunosuppressive",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8116217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of septic shock when blood pressure is poorly responsive to fluid resuscitation and vasopressor therapy; treatment of thyroid storm",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8116164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hydrocortisone may be confused with hydrocodone, hydroxychloroquine, hydrochlorothiazide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cortef&reg; may be confused with Coreg&reg;, Lortab&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HCT (occasional abbreviation for hydrocortisone) is an error-prone abbreviation (mistaken as hydrochlorothiazide)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Solu-CORTEF&reg; may be confused with Solu-MEDROL&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8116247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, bradycardia, cardiac arrest, cardiomegaly, circulatory collapse, congestive heart failure, edema, fat embolism, hypertension, hypertrophic cardiomyopathy (premature infants), myocardial rupture (post MI), syncope, tachycardia, thromboembolism, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Delirium, depression, emotional instability, euphoria, hallucinations, headache, insomnia, intracranial pressure increased, malaise, mood swings, nervousness, neuritis, neuropathy, personality changes, pseudotumor cerebri, psychic disorders, psychoses, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, allergic dermatitis, alopecia, bruising, burning/tingling, dry scaly skin, edema, erythema, hirsutism, hyper-/hypopigmentation, impaired wound healing, petechiae, rash, skin atrophy, skin test reaction impaired, sterile abscess, striae, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal suppression, alkalosis, amenorrhea, carbohydrate intolerance increased, Cushing's syndrome, diabetes mellitus, glucose intolerance, growth suppression, hyperglycemia, hyperlipidemia, hypokalemia, hypokalemic alkalosis, menstrual irregularities, negative nitrogen balance, pituitary-adrenal axis suppression, potassium loss, protein catabolism, sodium and water retention, sperm motility increased/decreased, spermatogenesis increased/decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appetite increased, bowel dysfunction (intrathecal administration), indigestion, nausea, pancreatitis, peptic ulcer, gastrointestinal perforation, ulcerative esophagitis, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder dysfunction (intrathecal administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytosis (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatomegaly, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy (at injection site), postinjection flare (intra-articular use), thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, necrosis (femoral and humoral heads), Charcot-like arthropathy, fractures, muscle mass loss, muscle weakness, myopathy, osteoporosis, tendon rupture, vertebral compression fractures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, exophthalmoses, glaucoma, intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abnormal fat deposits, anaphylaxis, avascular necrosis, diaphoresis, hiccups, hypersensitivity reactions, infection, secondary malignancy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8116223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydrocortisone or any component of the formulation; serious infections, except septic shock or tuberculous meningitis; viral, fungal, or tubercular skin lesions; I.M. administration contraindicated in idiopathic thrombocytopenia purpura; intrathecal administration of  injection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8116244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF or hypertension; long-term use has been associated with fluid retention and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head injury: Increased mortality was observed in patients receiving high-dose I.V. methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarct (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Oral steroid treatment is not recommended for the treatment of acute optic neuritis; may increase frequency of new episodes and does not affect short- or long-term visual outcomes. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8116271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8116272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8116276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Hydrocortisone interferes with calcium absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease hydrocortisone levels. Avoid cat's claw, echinacea (have immunostimulant properties).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8116218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8116219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Hydrocortisone crosses the placenta. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8116221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8116222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids are excreted in breast milk and endogenous hydrocortisone is also found in human milk; the effect of maternal hydrocortisone intake is not known.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8116345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic use of corticosteroids may require a diet with increased potassium, vitamins A, B",
"     <sub>",
"      6",
"     </sub>",
"     , C, D, folate, calcium, zinc, phosphorus, and decreased sodium. Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8116382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (A-Hydrocort Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $2.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Solu-CORTEF Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $6.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (1): $12.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $26.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (1): $50.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cortef Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (50): $24.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $83.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $159.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Hydrocortisone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (50): $16.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $57.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $78.81",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8116350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum glucose, electrolytes; blood pressure, weight, presence of infection; monitor IOP with therapy &gt;6 weeks; bone mineral density, growth in children",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F8116302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: AM: 5-25 mcg/dL (SI: 138-690 nmol/L), PM: 2-9 mcg/dL (SI: 55-248 nmol/L) depending on test, assay",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biocort (PH);",
"     </li>",
"     <li>",
"      Clovisone (PH);",
"     </li>",
"     <li>",
"      Colifoam (AT);",
"     </li>",
"     <li>",
"      Coripen (UY);",
"     </li>",
"     <li>",
"      Cort-S (IN);",
"     </li>",
"     <li>",
"      Cortifoam (IL);",
"     </li>",
"     <li>",
"      Cortin (PH);",
"     </li>",
"     <li>",
"      Cortis-100 (PH);",
"     </li>",
"     <li>",
"      Dhartisone-100 (ID, MY);",
"     </li>",
"     <li>",
"      Efcortelan Soluble (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Fridalit (AR);",
"     </li>",
"     <li>",
"      Hidrocort (VE);",
"     </li>",
"     <li>",
"      Hidrocortif (EC);",
"     </li>",
"     <li>",
"      Hycort (MY, PH);",
"     </li>",
"     <li>",
"      Hycortil (PH);",
"     </li>",
"     <li>",
"      Hydro-Adreson Aquosum (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Hydrocort (IL);",
"     </li>",
"     <li>",
"      Hydrocortison (DE);",
"     </li>",
"     <li>",
"      Hydrocortisone Upjohn (FR);",
"     </li>",
"     <li>",
"      Hydrocortone (AT, PT);",
"     </li>",
"     <li>",
"      Hydrotopic (PH);",
"     </li>",
"     <li>",
"      Hyson (TW);",
"     </li>",
"     <li>",
"      Novocortril (PE);",
"     </li>",
"     <li>",
"      Radicortin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Solu Cortef (AE, BD, BE, BF, BH, BJ, CH, CI, CL, CO, CY, DK, EC, EE, EG, ET, FI, GB, GH, GM, GN, GR, HK, HN, IE, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, OM, PE, PH, PK, QA, RU, SA, SC, SD, SE, SG, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Solu Cortef M.O.V. (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Solu-Cortef (AU, CN, EC, NZ, VE);",
"     </li>",
"     <li>",
"      Solu-Tisone (TW);",
"     </li>",
"     <li>",
"      Stericort (PH);",
"     </li>",
"     <li>",
"      Syntesor (PH);",
"     </li>",
"     <li>",
"      Zonac (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8116300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8116303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hydrocortisone sodium succinate (water soluble): Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biologic: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as 17-hydroxysteroids and 17-ketosteroids)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham E and Evans T, &ldquo;Corticosteroids and Septic Shock [editorial],&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):886-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/12186608/pubmed\" id=\"12186608\" target=\"_blank\">",
"        12186608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ahmet A, Kim H, and Spier S, &ldquo;Adrenal Suppression: A Practical Guide to the Screening and Management of this Under-Recognized Complication of Inhaled Corticosteroid Therapy,&rdquo;",
"      <i>",
"       Allergy Asthma Clin Immunol",
"      </i>",
"      , 2011, 7:13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/21867553/pubmed\" id=\"21867553\" target=\"_blank\">",
"        21867553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Annane D, Sebille V, Charpentier C, et al, &ldquo;Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):862-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/12186604/pubmed\" id=\"12186604\" target=\"_blank\">",
"        12186604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arlt W and Allolio B, &ldquo;Adrenal Insufficiency,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9372):1881-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/12788587/pubmed\" id=\"12788587\" target=\"_blank\">",
"        12788587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beck RW, Cleary PA, Anderson MM Jr, et al, &ldquo;A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis. The Optic Neuritis Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 326(9):581-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/1734247/pubmed\" id=\"1734247\" target=\"_blank\">",
"        1734247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bahn RS (Chair), Burch HB, Cooper DS, et al, &ldquo;Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,&rdquo;",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2011, 21(6):593-646.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/ 21510801/pubmed\" id=\" 21510801\" target=\"_blank\">",
"        21510801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratton SL, Chestnut RM, Ghajar J, et al, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury. XV. Steroids,&rdquo;",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2007, 24(Suppl 1):91-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/17511554/pubmed\" id=\"17511554\" target=\"_blank\">",
"        17511554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brierley J, Carcillo JA, Choong K, et al, &ldquo;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):666-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/19325359/pubmed\" id=\"19325359\" target=\"_blank\">",
"        19325359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper MS and Stewart PM, &ldquo;Corticosteroid Insufficiency in Acutely Ill Patients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/12594318/pubmed\" id=\"12594318\" target=\"_blank\">",
"        12594318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coursin DB and Wood KE, &ldquo;Corticosteroid Supplementation for Adrenal Insufficiency,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 287(2):236-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/11779267/pubmed\" id=\"11779267\" target=\"_blank\">",
"        11779267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Jonghe B, Sharshar T, Lefaucheur JP, et al, &ldquo;Paresis Acquired in the Intensive Care Unit. A Prospective Multicenter Study,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(22):2859-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/12472328/pubmed\" id=\"12472328\" target=\"_blank\">",
"        12472328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo; [published correction appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6],",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards P, Arango M, Balica L, et al, &ldquo;Final Results of MRC Crash, A Randomized Placebo-Controlled Trial of Intravenous Corticosteroid in Adults With Head Injury - Outcomes at 6 Months,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 365(9475):1957-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/15936423/pubmed\" id=\"15936423\" target=\"_blank\">",
"        15936423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gamsu HR, Mullinger BM, Donnai P, et al, &ldquo;Antenatal Administration of Betamethasone to Prevent Respiratory Distress Syndrome in Preterm Infants: Report of a UK Multicentre Trial,&rdquo;",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1989, 96(4):401-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/2665800/pubmed\" id=\"2665800\" target=\"_blank\">",
"        2665800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta P and Bhatia V, &ldquo;Corticosteroid Physiology and Principles of Therapy,&rdquo;",
"      <i>",
"       Indian J Pediatr",
"      </i>",
"      , 2008, 75(10):1039-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/19023528/pubmed\" id=\"19023528\" target=\"_blank\">",
"        19023528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hotchkiss RS and Karl IE, &ldquo;The Pathophysiology and Treatment of Sepsis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(2):138-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/12519925/pubmed\" id=\"12519925\" target=\"_blank\">",
"        12519925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2010, 105(3):501-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/20068560/pubmed\" id=\"20068560\" target=\"_blank\">",
"        20068560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liggins GC and Howie RN, &ldquo;A Controlled Trial of Antepartum Glucocorticoid Treatment of Respiratory Distress Syndrome in Premature Infants,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1972, 50:515-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/4561295/pubmed\" id=\"4561295\" target=\"_blank\">",
"        4561295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maguire AM, Ambler GR, Moore B, et al, &ldquo;Prolonged Hypocortisolemia in Hydrocortisone Replacement Regimens in Adrenocorticotrophic Hormone Deficiency,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 120(1):e164-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/17576782/pubmed\" id=\"17576782\" target=\"_blank\">",
"        17576782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marik PE, Pastores SM, Annane D, et al, &ldquo;Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(6):1937-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/18496365/pubmed\" id=\"18496365\" target=\"_blank\">",
"        18496365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGee S and Hirschmann J, &ldquo;Use of Corticosteroids in Treating Infectious Diseases,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2008, 168(10):1034-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/18504331/pubmed\" id=\"18504331\" target=\"_blank\">",
"        18504331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostensen M, &ldquo;Optimisation of Antirheumatic Drug Treatment in Pregnancy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(6):486-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/7882637/pubmed\" id=\"7882637\" target=\"_blank\">",
"        7882637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(12):968-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/14745915/pubmed\" id=\"14745915\" target=\"_blank\">",
"        14745915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed, BR, &ldquo;Dermatologic Drugs, Pregnancy, and Lactation. A Conservative Guide,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1997, 133(7):894-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/9236528/pubmed\" id=\"9236528\" target=\"_blank\">",
"        9236528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts I, Yates D, Sandercock P, et al, &ldquo;Effect of Intravenous Corticosteroids on Death Within 14 days in 10,008 Adults With Clinically Significant Head Injury (MRC CRASH trial): Randomised Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2004, 364(9442):1321-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/15474134/pubmed\" id=\"15474134\" target=\"_blank\">",
"        15474134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salem M, Tainsh RE Jr, Bromberg J, et al, &ldquo;Perioperative Glucocorticoid Coverage. A Reassessment 42 Years After Emergence of a Problem,&rdquo;",
"      <i>",
"       Ann Surg",
"      </i>",
"      , 1994, 219(4):416-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/8161268/pubmed\" id=\"8161268\" target=\"_blank\">",
"        8161268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Speiser PW, Azziz R, Baskin LS, et al, \"Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(9):4133-60; published errratum appears in",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(11):5137.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sprung CL, Annane D, Keh D, et al, &ldquo;Hydrocortisone Therapy for Patients With Septic Shock,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(2):111-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/48/8969/abstract-text/18184957/pubmed\" id=\"18184957\" target=\"_blank\">",
"        18184957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Technical Report: Congenital Adrenal Hyperplasia,&rdquo; American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics,",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(6):1511-8.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9144 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-3918385851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8969=[""].join("\n");
var outline_f8_48_8969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116174\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116175\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116204\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116314\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116312\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116315\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897565\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897566\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116380\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116180\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116346\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116281\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116215\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116217\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116164\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116247\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116223\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116244\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116271\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116272\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116276\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116218\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116219\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116221\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116222\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116345\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116382\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116350\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116302\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961979\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116300\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116303\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9144\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9144|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/36/35398?source=related_link\">",
"      Hydrocortisone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/46/22249?source=related_link\">",
"      Hydrocortisone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/54/21352?source=related_link\">",
"      Hydrocortisone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/25/19861?source=related_link\">",
"      Hydrocortisone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/33/7702?source=related_link\">",
"      Hydrocortisone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_48_8970="Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)";
var content_f8_48_8970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/48/8970/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/48/8970/contributors\">",
"     William H Parker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/48/8970/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/48/8970/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/48/8970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/48/8970/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/48/8970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7666316\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic techniques provide minimally invasive options for many gynecologic procedures. Myomectomy, the removal of uterine leiomyomas (myomas or fibroids), can be performed laparoscopically in selected women. Other laparoscopic procedures have been developed for leiomyoma treatment, including uterine artery occlusion and myolysis, but these are not commonly used.",
"   </p>",
"   <p>",
"    Uterine leiomyomas are the most common type of pelvic tumor in women, with an approximately 70 to 80 percent lifetime risk [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. There are a wide variety of treatments for leiomyomas, both pharmacologic and surgical. The choice of treatments depends upon many factors, including characteristics of the myomas, the patient, and surgical expertise.",
"   </p>",
"   <p>",
"    Laparoscopic myomectomy and other laparoscopic procedures for uterine leiomyomas will be reviewed here. Abdominal, hysteroscopic, and vaginal myomectomy, as well as other approaches to the management of leiomyomas, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link\">",
"     \"Abdominal myomectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=see_link\">",
"     \"Hysteroscopic myomectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=see_link\">",
"     \"Prolapsed uterine leiomyoma (fibroid)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2968896\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic myomectomy is primarily used to remove intramural or subserosal leiomyomas (",
"    <a class=\"graphic graphic_figure graphicRef53241 \" href=\"UTD.htm?30/16/30978\">",
"     figure 1",
"    </a>",
"    ). Intracavitary myomas (submucosal and some intramural myomas that protrude into the endometrial cavity) (",
"    <a class=\"graphic graphic_figure graphicRef59668 \" href=\"UTD.htm?26/32/27143\">",
"     figure 2",
"    </a>",
"    ) are difficult to remove during laparoscopic myomectomy. In addition, hysteroscopic myomectomy is the procedure of choice when only intracavitary myomas are removed, since it offers the advantages of a short recovery and minimal perioperative morbidity. Women with both submucosal and",
"    <span class=\"nowrap\">",
"     intramural/subserosal",
"    </span>",
"    myomas may be candidates for concomitant laparoscopic and hysteroscopic myomectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=see_link&amp;anchor=H2#H2\">",
"     \"Hysteroscopic myomectomy\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate candidates for laparoscopic myomectomy are women with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptomatic uterine leiomyoma(s)",
"     </li>",
"     <li>",
"      Leiomyomas are the appropriate size, number, and location for laparoscopic removal (See",
"      <a class=\"local\" href=\"#H3730094\">",
"       'Candidates for laparoscopic myomectomy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hysteroscopic myomectomy is not feasible",
"     </li>",
"     <li>",
"      An abdominal approach is required to treat intraabdominal pathology other than leiomyomas",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2968903\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indications for laparoscopic myomectomy are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal uterine bleeding",
"     </li>",
"     <li>",
"      Bulk-related symptoms &ndash;",
"      <span class=\"nowrap\">",
"       pelvic/abdominal",
"      </span>",
"      pain or pressure; pressure on the urinary or gastrointestinal tract resulting in urinary (eg, urinary frequency, urinary incontinence, hydronephrosis) or bowel symptoms (eg, constipation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dysmenorrhea is an infrequent indication for myomectomy. Dysmenorrhea is more commonly associated with conditions (eg, endometriosis) other than with myomas. Myomectomy or other fibroid-specific treatment for the indication of dysmenorrhea should be performed only when other therapies for dysmenorrhea have failed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=see_link\">",
"     \"Treatment of primary dysmenorrhea in adult women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2968910\">",
"    <span class=\"h3\">",
"     Unproven indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy should be performed only for women in whom the procedure is likely to ameliorate a specific symptom. Indications for which the benefit of laparoscopic (or abdominal) myomectomy remains unproven include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evaluation of ovarian or uterine malignancy",
"     </li>",
"     <li>",
"      Infertility (removal of fibroids with a submucous component is associated with increased fertility)",
"     </li>",
"     <li>",
"      Prevention of obstetric complications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These indications are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H7945019#H7945019\">",
"     \"Abdominal myomectomy\", section on 'Unproven indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2968938\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic myomectomy is contraindicated in women in whom laparoscopy or uterine conservation are contraindicated (eg, medical comorbidities, cervical or uterine cancer). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41735?source=see_link\">",
"     \"Overview of the principles of medical consultation and perioperative medicine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2969212\">",
"    <span class=\"h1\">",
"     CHOOSING A TREATMENT APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2969220\">",
"    <span class=\"h2\">",
"     Myomectomy versus other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of treatment for women with uterine leiomyomas is guided by the type of symptoms: abnormal bleeding or bulk-related (eg, pelvic",
"    <span class=\"nowrap\">",
"     pain/pressure).",
"    </span>",
"    There are a variety of treatment approaches, both pharmacologic and surgical.",
"   </p>",
"   <p>",
"    The choice between myomectomy and other treatments is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H7944123#H7944123\">",
"     \"Abdominal myomectomy\", section on 'Myomectomy versus other treatment approaches'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link&amp;anchor=H30#H30\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\", section on 'Choosing a long-term treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7666273\">",
"    <span class=\"h2\">",
"     Choosing the surgical approach for myomectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic myomectomy offers several advantages compared with abdominal myomectomy, including decreased morbidity and a shorter recovery. However, the wide application of laparoscopic myomectomy is limited by the characteristics of myomas that can be reasonably removed and the surgical expertise required (eg, laparoscopic suturing) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/4\">",
"     4",
"    </a>",
"    ]. Robot-assisted myomectomy is a relatively new approach. Hysteroscopic myomectomy is the procedure of choice for women with intracavitary myomas (submucosal and some intramural myomas that protrude into the endometrial cavity).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3730094\">",
"    <span class=\"h3\">",
"     Candidates for laparoscopic myomectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining whether a woman is a candidate for laparoscopic myomectomy depends upon the location, size, and number of leiomyomas, although parameters for these vary with surgical expertise. These criteria are used to ensure that women undergoing the procedure avoid perioperative complications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    conversion to laparotomy. Preoperative imaging is important to assess the precise characteristics of the tumors. (See",
"    <a class=\"local\" href=\"#H26569434\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Important factors regarding the location of fibroids include the depth of penetration into the myometrium and position relative to important structures (eg, uterine vessels, fallopian tubes). Pedunculated subserosal fibroids are the easiest to remove, but myomas in other locations can also be excised laparoscopically. In addition, many surgeons find anterior or fundal myomas easier to remove than those that are posterior. Performing laparoscopic myomectomy in women with large or numerous myomas is likely to be time consuming, particularly since morcellation is usually required. In addition, removal of such fibroids may lead to increased blood loss, which is better prevented and controlled during open myomectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link&amp;anchor=H1388946#H1388946\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\", section on 'Intraoperative measures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few data address the optimal criteria for a successful laparoscopic myomectomy, and the ability to successfully perform a laparoscopic myomectomy also depends in large part on surgical expertise. The largest study was a prospective multicenter study of 2050 women undergoing laparoscopic myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/5\">",
"     5",
"    </a>",
"    ]. Leiomyoma characteristics that were significantly associated with major complications (eg, bleeding requiring blood transfusion, visceral injury, procedural failure) included: size of myoma &gt;5 cm; &gt;3 myomas removed; and intraligamentous location; intramural myomas were significantly associated with an increase in minor, but not major, complications (eg, fever, uterine manipulator injuries).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3730101\">",
"    <span class=\"h3\">",
"     Laparoscopic versus open myomectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In appropriately selected patients, laparoscopic myomectomy has lower overall morbidity and a shorter recovery time than open myomectomy.",
"   </p>",
"   <p>",
"    A systematic review of six randomized trials including 576 women compared laparoscopic with abdominal myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/6\">",
"     6",
"    </a>",
"    ]. Laparoscopic myomectomy had a statistically significant increase in operative duration (13 min longer), but a decrease in blood loss (34 ml less). However, these differences are small and unlikely to be clinically significant. The overall risk of complication was significantly lower for laparoscopic myomectomy (OR 0.47; 95% CI 0.26-0.85), but there was no statistically significant difference in the risk of major complications (eg, hemorrhage requiring transfusion, visceral injury, thromboembolism) (OR 0.49; 95% CI 0.09-2.70); however, the analysis lacked sufficient statistical power to detect this difference. Two of the trials reported that significantly more patients in the laparoscopic group had fully recuperated by postoperative day 15. Although the data were too heterogeneous for meta-analysis, the shorter recovery time for laparoscopic surgery is well established.",
"   </p>",
"   <p>",
"    Regarding long-term outcomes, follow-up ranged widely across studies in the meta-analysis from 6 to 52 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/6\">",
"     6",
"    </a>",
"    ]. There was no significant difference in the rate of recurrent myomas laparoscopic and open myomectomy (20 versus 18 percent; OR 1.2, 95% CI 0.4-3.0), although this analysis also lacked statistical power. Interestingly, some data suggest that a laparoscopic approach results in less severe adhesive disease, particularly fewer adnexal adhesions, which may impact fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1881385\">",
"     'Adhesive disease'",
"    </a>",
"    below.) Further randomized trials are needed to compare between these two procedures.",
"   </p>",
"   <p>",
"    In summary, laparoscopic myomectomy is a minimally invasive procedure with a shorter recovery and a lower overall risk of complications than abdominal myomectomy. More data are needed about the comparative risks of major complications and fibroid persistence or recurrence. Patient eligibility and access to trained surgeons limit the availability of this procedure. Given the available data, we suggest laparoscopic rather than open myomectomy for women with leiomyomas when technically feasible (depending upon size, number, and location) and who have easy access to a surgeon with advanced laparoscopic skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10497672\">",
"    <span class=\"h2\">",
"     Alternative laparoscopic techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1198933\">",
"    <span class=\"h3\">",
"     Robot-assisted laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Robot-assisted laparoscopic myomectomy may decrease technical difficulty by making laparoscopic suturing easier than during conventional laparoscopic procedures. However, use of robot-assisted laparoscopy is expensive, and, currently, there are fewer surgeons with expertise in robot-assisted than in conventional laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Robot-assisted laparoscopic myomectomy is associated with decreased blood loss and recovery time compared with open myomectomy, but appears to increase operative duration, based upon observational data [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. As an example, in one case-control study (n = 125), robotic-assisted compared with open procedures had a significant decrease in blood loss (226 versus 459 ml), change in postoperative hematocrit (5.1 versus 7.1 percent), length of hospital stay (0.5 versus 3.3 days), number of days to regular diet (0.9 versus 2.3 days), and febrile morbidity (1.3 percent versus 38 percent), despite significantly longer robotic surgical times (3.2 versus 2.3 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data comparing robot-assisted with conventional laparoscopic myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]. In the largest study to-date, a retrospective case series of 575 myomectomies (68.3 percent open, 16.2 percent conventional laparoscopic, and 5.5 percent robot-assisted) reported that robotic-assisted myomectomy was associated with blood loss (robot-assisted: 150mL and conventional laparoscopic: 100mL) and operative duration (181 and 155 minutes) that were comparable to conventional laparoscopic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/9\">",
"     9",
"    </a>",
"    ]. Case selection bias is likely in retrospective studies, however, which makes these low quality data. &nbsp;",
"   </p>",
"   <p>",
"    Some data suggest that obesity is not associated with poor surgical outcomes in patients undergoing robotic myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not known whether robotic technology results in a more secure myometrial closure, and thus, in a lower risk of subsequent uterine rupture; there is only one report of pregnancy after a robot-assisted myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/12\">",
"     12",
"    </a>",
"    ]. Although robotic technology facilitates laparoscopic suturing, the lack of haptic (tactile) feedback may limit the ability to hold tension on a suture. However, the third operative arm instrument enables the surgeon to hold tension on the suture while he or she sutures with the other arms. Additionally, recently introduced barbed sutures (eg, Quill&trade; Self-Retaining System, V-Loc&trade; Absorbable Wound Closure Device) facilitate suture fixation in myometrial tissue during both robotic and laparoscopic myomectomy, also decreasing the need to hold tension on sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link&amp;anchor=H20#H20\">",
"     \"Principles of abdominal wall closure\", section on 'Skin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10497613\">",
"    <span class=\"h3\">",
"     Single port laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single port laparoscopy, or laparoendoscopic single-site surgery (LESS), is the most recent laparoscopic innovation. Successful LESS myomectomy has been reported, but the data are limited to small case series and small fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Further study is needed to evaluate this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9029?source=see_link\">",
"     \"Laparoendoscopic single-site (single port) surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The technique for LESS myomectomy was described by one surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/20\">",
"     20",
"    </a>",
"    ]. The technique involved the placement of three 5 mm trocars through a common umbilical incision, but through separate fascial perforations. A harmonic scalpel and blunt dissection were used to remove a 4 cm transmural posterior fundal myoma and the uterine defect was repaired in layers using bidirectional barbed suture. After removal of the trocars, a fascial incision connecting the perforations was made to facilitate removal of the myoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26569406\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative evaluation and preparation are similar for laparoscopic and abdominal myomectomy. Information specific to laparoscopic myomectomy is discussed in this section. The remainder of the information can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H426525#H426525\">",
"     \"Abdominal myomectomy\", section on 'Preoperative evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H426783#H426783\">",
"     \"Abdominal myomectomy\", section on 'Preoperative preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26569413\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with symptomatic fibroids should be counseled about other medical, interventional radiology, and surgical options for treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link&amp;anchor=H30#H30\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\", section on 'Choosing a long-term treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential complications of the procedure, including conversion to laparotomy and the likelihood of recurrence of fibroid-associated symptoms should also be reviewed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H25049781#H25049781\">",
"     \"Abdominal myomectomy\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H7665571#H7665571\">",
"     \"Abdominal myomectomy\", section on 'Persistent or new myomas'",
"    </a>",
"    .) This discussion should be documented on the surgical consent form and in the medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26569434\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are planning myomectomy should undergo imaging to confirm the presence of uterine leiomyomas rather than other pelvic pathology. In addition, incidental findings of other lesions (eg, ovarian cyst) may impact surgical planning.",
"   </p>",
"   <p>",
"    Pelvic sonography is typically the initial imaging study. Ultrasound can confirm the presence of leiomyomas and their approximate number and location [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/21\">",
"     21",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) provides more accurate information regarding myoma size, number, and location than other imaging modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/21\">",
"     21",
"    </a>",
"    ]. For women who are being evaluated for possible laparoscopic myomectomy, this information may help the surgeon determine whether laparoscopic surgery is feasible and may help avoid missing myomas not palpable during laparoscopic surgery. MRI is also the best modality to diagnose adenomyosis, which can mimic leiomyomas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    make myomectomy more difficult. MRI is also indicated if uterine sarcoma is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=see_link&amp;anchor=H7#H7\">",
"     \"Uterine adenomyosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link&amp;anchor=H21562275#H21562275\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\", section on 'Choice of imaging modality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging of uterine leiomyomas is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H5287506#H5287506\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link&amp;anchor=H1430514#H1430514\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26569841\">",
"    <span class=\"h2\">",
"     GnRH agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative use of gonadotropin releasing hormone agonists reduces the size of myomas, and may theoretically allow a laparoscopic rather than abdominal approach in some women. No studies have evaluated this approach. Disadvantages of these agents are that they may make removal of myomas more difficult and may increase the risk of persistent myomas. In our practice, we do not pretreat with these agents prior to laparoscopic myomectomy.",
"   </p>",
"   <p>",
"    The use of gonadotropin releasing hormone agonists prior to myomectomy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H623653#H623653\">",
"     \"Abdominal myomectomy\", section on 'Reducing uterine size with GnRH agonists'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link&amp;anchor=H1389439#H1389439\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\", section on 'GnRH agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26569855\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing laparoscopic myomectomy (major surgery, defined as &gt;30 minutes duration) are at low to moderate risk for venous thromboembolism and require appropriate thromboprophylaxis, whether mechanical or pharmacologic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link&amp;anchor=H17332175#H17332175\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\", section on 'Thromboprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26569862\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis is typically not administered for laparoscopic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/22\">",
"     22",
"    </a>",
"    ]. The risk of surgical site infection is low in laparoscopic procedures in which the vagina or bowel are not entered [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1748360\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic myomectomy requires general anesthesia, since pneumoperitoneum and potential upper abdominal manipulation make it preferable to have full abdominal anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7666064\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic steps of laparoscopic myomectomy are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insert laparoscopic ports",
"     </li>",
"     <li>",
"      Apply measures to reduce blood loss",
"     </li>",
"     <li>",
"      Make uterine incision(s)",
"     </li>",
"     <li>",
"      Remove myomas",
"     </li>",
"     <li>",
"      Close uterine defects",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26570122\">",
"    <span class=\"h2\">",
"     Laparoscopic port placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Port placement is based upon the position and size of the myomas to be removed, usually higher than the uterine fundus to allow access to the myomas. A left upper quadrant approach may be used for initial access if uterine size is near or above the umbilicus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12168?source=see_link&amp;anchor=H13#H13\">",
"     \"Gynecologic laparoscopy: Non-umbilical entry sites\", section on 'Left upper quadrant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the initial port has been placed, the camera is inserted and the pelvis and abdomen surveyed. The feasibility of the procedure is assessed. If there are unexpected findings (eg, extensive adhesive disease) that preclude laparoscopic myomectomy, the procedure should be converted to laparotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H25049716#H25049716\">",
"     \"Abdominal myomectomy\", section on 'Procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Placement of two ports on either the patient's right side for right-handed surgeons or left side for left-handed surgeons makes laparoscopic suturing more ergonomic. These include a 12 mm port at approximately 2 cm medial to the iliac crest to allow access for adequately sized curved needles and an ipsilateral 5 mm port medial and slightly cephalad to the larger port [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/26\">",
"     26",
"    </a>",
"    ]. A contralateral 5 mm port is also placed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26570231\">",
"    <span class=\"h2\">",
"     Measures to reduce blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy may involve significant blood loss. Bleeding can be prevented or decreased with mechanical or pharmacologic methods. Allogeneic blood transfusion can be avoided by using methods of autologous blood transfusion (autologous blood donation, intraoperative and postoperative blood salvage, or acute normovolemic [isovolemic] hemodilution).",
"   </p>",
"   <p>",
"    Techniques to reduce blood loss during myomectomy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link&amp;anchor=H1388946#H1388946\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\", section on 'Intraoperative measures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To control bleeding from large vessels within a myometrial defect, we desiccate briefly with bipolar electrosurgical paddles. Excessive desiccation devascularizes the myometrium and should be avoided, since it may increase the risk of uterine rupture in subsequent pregnancy. (See",
"    <a class=\"local\" href=\"#H3565445\">",
"     'Uterine rupture during pregnancy following myomectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26570315\">",
"    <span class=\"h2\">",
"     Uterine incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transverse myometrial incision, rather than a vertical incision, allows more ergonomic laparoscopic suturing of the uterine defect. The incision is made directly over the myoma and carried deeply until definite myoma tissue and the avascular plane just deep to the capsule of the myoma are noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26570323\">",
"    <span class=\"h2\">",
"     Removal and morcellation of myomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques for removing myomas vary [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In our practice, we grasp each myoma with a tenaculum for traction and use blunt and sharp dissection to separate the plane between the myometrium and myoma.",
"   </p>",
"   <p>",
"    Morcellation of the myoma with an electromechanical device is accomplished under direct vision and away from vital structures to avoid inadvertent injury. The myoma tissue is removed through the 12 mm port and sent for pathologic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26570330\">",
"    <span class=\"h2\">",
"     Closure of uterine defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed absorbable sutures are placed in one, two or three layers, depending upon the depth of the myometrial defect. In our practice, we use size 0 polydioxanone (eg, PDS&trade;). Other sutures, including polyglactin (Vicryl",
"    <sup>",
"     TM",
"    </sup>",
"    ) or barbed suture, may be used, although no studies have compared the use of different sutures with regard to strength of the uterine wound. Entrance into the uterine cavity can usually be detected due to the different texture and color of the endometrium. Some surgeons place",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    into the cavity via a transcervical catheter so that the dye can be seen if the cavity is entered. We close all defects, including the serosa following removal of a pedunculated fibroid.",
"   </p>",
"   <p>",
"    We adhere as closely as possible to the surgical technique for abdominal myomectomy. It is controversial whether reapproximation of the myometrium via laparoscopic suturing gives the uterine wall the same strength as multilayer closure at laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The security of the closure may impact the risk of uterine rupture in subsequent pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H7664470#H7664470\">",
"     \"Abdominal myomectomy\", section on 'Closure of uterine defects'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3565445\">",
"     'Uterine rupture during pregnancy following myomectomy'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    At the close of the procedure, the pelvis and abdomen are irrigated, the fluid suctioned, and measures to prevent adhesion formation are applied, if desired. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=see_link\">",
"     \"Preventing postoperative peritoneal adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1390846\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are similar for laparoscopic and abdominal myomectomy. Information specific to laparoscopic myomectomy is discussed in this section. The remainder of the information can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H25049781#H25049781\">",
"     \"Abdominal myomectomy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1880753\">",
"    <span class=\"h2\">",
"     Hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In series of 500 or more laparoscopic myomectomies, the rate of hemorrhage or blood transfusion varied widely from 0.1 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/5,32,33\">",
"     5,32,33",
"    </a>",
"    ]. The average blood loss reported was 80 to 248 ml (range 20 to 1000 mL) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention and management of blood loss during myomectomy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1881253\">",
"    <span class=\"h2\">",
"     Fever and infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever occurs in many women following myomectomy, but a localized source is often not identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H7664617#H7664617\">",
"     \"Abdominal myomectomy\", section on 'Fever and infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation and management of postoperative fever are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=see_link\">",
"     \"Postoperative fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1881606\">",
"    <span class=\"h2\">",
"     Bowel or bladder injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral injury during laparoscopic myomectomy is rare. In series of 500 or more laparoscopic myomectomies, the rate of bowel injury was 0 to 0.04 and of bladder injury was 0 to 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/5,32\">",
"     5,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1880877\">",
"    <span class=\"h2\">",
"     Conversion to laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conversion to laparotomy occurs in 1 to 2 percent of laparoscopic myomectomy procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. A laparoscopic myomectomy may be converted to a laparotomy if initial evaluation reveals pathology that precludes a laparoscopic approach or to aid management of an intraoperative complication (eg, hemorrhage).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1881385\">",
"    <span class=\"h2\">",
"     Adhesive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesion formation after myomectomy has been well documented. Studies in which second look laparoscopy has been performed following laparoscopic myomectomy have reported intraabdominal adhesions in 36 to 66 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, laparoscopic myomectomy may result in fewer adhesions than abdominal myomectomy. This was suggested by a prospective cohort study (n = 28) in which second look laparoscopy following laparoscopic compared with abdominal myomectomy revealed adhesions in fewer women (4 of 14 versus 9 of 14 women) and less dense adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/7\">",
"     7",
"    </a>",
"    ]. Further study is needed to validate these findings. (See",
"    <a class=\"local\" href=\"#H7666273\">",
"     'Choosing the surgical approach for myomectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A detailed discussion of methods of adhesion prevention can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=see_link\">",
"     \"Preventing postoperative peritoneal adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1881709\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and management of other complications, such as ileus or wound infection, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=see_link\">",
"     \"Small bowel obstruction: Causes and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link\">",
"     \"Postoperative ileus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1750441\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1881815\">",
"    <span class=\"h2\">",
"     Relief of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data regarding the rate of relief of symptoms following laparoscopic myomectomy. It is uncertain whether success rates can be extrapolated from abdominal myomectomy, which has been reported to relieve symptoms in approximately 80 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/2,40\">",
"     2,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1881843\">",
"    <span class=\"h2\">",
"     Persistent or new myomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a multicenter retrospective cohort study of 512 women who underwent laparoscopic myomectomy, the rates of post-myomectomy myomas at five and eight years were 53 and 84 percent; however, the rates of reoperation were much lower, 7 and 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/41\">",
"     41",
"    </a>",
"    ]. Risk factors for the presence of leiomyomas were similar to those for open myomectomy, including: multiple myomas at time of surgery, uterine size &ge;13 weeks, and age &lt;36 years. In this study, pregnancy after myomectomy was associated with an increased risk of subsequent myomas, but this was contrary to findings of other studies of laparoscopic and open myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H7665571#H7665571\">",
"     \"Abdominal myomectomy\", section on 'Persistent or new myomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review of six randomized trials including 576 women that compared laparoscopic with open myomectomy found no significant difference in the rate of recurrent myomas between the two surgical approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/6\">",
"     6",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1881992\">",
"    <span class=\"h1\">",
"     INPATIENT POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic myomectomy is typically performed as an outpatient procedure or with a one day hospital stay. &nbsp;",
"   </p>",
"   <p>",
"    Routine postoperative care following myomectomy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H1747014#H1747014\">",
"     \"Abdominal myomectomy\", section on 'Inpatient postoperative care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1840958\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A woman is encouraged to resume her normal daily activities as quickly as is comfortable. Decisions regarding resumption of vaginal intercourse are made by the patient; there are no medical restrictions on sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients may return to work as soon as they have regained sufficient stamina and mobility.",
"   </p>",
"   <p>",
"    Routine postoperative instructions for patients can be found separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=see_link\">",
"     \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We see patients for a follow-up visit at two weeks postoperatively. The follow-up visit includes an evaluation for potential complications and an examination of the abdomen and wounds. We review the details of the surgery and pathology results with the patient. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1882151\">",
"    <span class=\"h1\">",
"     CONCEPTION AND PREGNANCY AFTER MYOMECTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1882187\">",
"    <span class=\"h2\">",
"     Interval to conception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who undergo myomectomy with significant uterine disruption should wait several months before attempting to conceive; recommendations for the interval to conception range from three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433213\">",
"    <span class=\"h2\">",
"     Fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a woman is having difficulty conceiving following a myomectomy, early assessment of the uterine cavity and fallopian tubes with a hysterosalpingogram is advisable [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues of fertility and leiomyomas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H7945234#H7945234\">",
"     \"Abdominal myomectomy\", section on 'Infertility'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=see_link\">",
"     \"Reproductive issues in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3565445\">",
"    <span class=\"h2\">",
"     Uterine rupture during pregnancy following myomectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy is associated with an increased risk of uterine rupture during subsequent pregnancy. Operative techniques, instruments and energy sources used during laparoscopic myomectomy often differ from those employed during laparotomy. Failure to adequately suture myometrial defects, lack of hemostasis within uterine defects with subsequent hematoma formation, or the excessive use electrosurgery with devascularization of the myometrium have all been postulated to interfere with myometrial wound healing and increase the potential for rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest study of laparoscopic myomectomy, 2050 women followed for an average of 42 months, there were 386 pregnancies and one uterine rupture (spontaneous rupture at 33 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/5\">",
"     5",
"    </a>",
"    ]. A review of published and unpublished cases yielded 19 instances of uterine rupture during pregnancy following laparoscopic myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/46\">",
"     46",
"    </a>",
"    ]. Almost all of the cases contained a deviation from standard technique, as described for abdominal myomectomy. In seven cases, the uterine defect was not repaired; in three cases, it was repaired with a single suture; in four cases, it was repaired in only one layer; and, in one case, only the serosa was closed. A multi-layered closure employed in only three cases. In 16 of the 19 cases, primarily monopolar or bipolar energy was used for hemostasis.",
"   </p>",
"   <p>",
"    Presently, it appears prudent for surgeons who perform laparoscopic myomectomy to adhere to time-tested techniques developed for abdominal myomectomy, including limited use of electrosurgery and use of multi-layered closure of myometrium. Yet, even with ideal surgical technique, individual wound healing characteristics may predispose to uterine rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many experts advise cesarean delivery as a conservative approach.",
"   </p>",
"   <p>",
"    Uterine rupture during pregnancy following myomectomy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=see_link&amp;anchor=H25#H25\">",
"     \"Pregnancy in women with uterine leiomyomas (fibroids)\", section on 'Management of patients with prior myomectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432882\">",
"    <span class=\"h1\">",
"     ALTERNATIVE LAPAROSCOPIC TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are ongoing efforts to develop minimally invasive treatments for fibroids. Methods that are performed laparoscopically are discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432917\">",
"    <span class=\"h2\">",
"     Uterine artery occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic uterine artery occlusion procedures have been investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. However, such techniques have distinct disadvantages compared with other minimally invasive approaches, such as laparoscopic myomectomy or uterine artery embolization.",
"   </p>",
"   <p>",
"    Myomas may shrink after uterine artery occlusion, but uterine volume is not reduced to the same extent as myomectomy. This, combined with the exposure of women to general anesthesia and abdominal incisions for both procedures, makes myomectomy the preferred procedure. No studies have compared these two procedures.",
"   </p>",
"   <p>",
"    Uterine artery embolization has been compared with laparoscopic uterine artery occlusion, since both treat fibroids with occlusion of the uterine blood supply. Laparoscopic occlusion has some advantages compared with uterine artery embolization, including: (1) avoids introduction of foreign bodies (eg, polyvinyl alcohol particles, coils); (2) provides laparoscopic assessment of the pelvis and abdomen; and (3) was associated with less postoperative pain in a prospective cohort study of 46 women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/48\">",
"     48",
"    </a>",
"    ]. However, these advantages are superseded by several disadvantages, including that laparoscopic occlusion requires general anesthesia, is invasive, and requires a skilled laparoscopic surgeon. Also, uterine artery embolization performed better in a small randomized trial (n = 58) comparing the two methods, as measured by the mean uterine volume reduction (51 versus 33 percent) and rate of recurrent symptoms (17 verus 48 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/53\">",
"     53",
"    </a>",
"    ]. Thus, women who are planning treatment of leiomyomas with blockage of the uterine blood supply are better treated with uterine artery embolization than laparoscopic uterine artery occlusion.",
"   </p>",
"   <p>",
"    Thus, we suggest either laparoscopic myomectomy or uterine artery embolization rather than laparoscopic uterine artery occlusion. Choosing between myomectomy and uterine artery embolization is discussed separately. Use of concurrent laparoscopic myomectomy and uterine artery ligation has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link&amp;anchor=H26149120#H26149120\">",
"     \"Abdominal myomectomy\", section on 'Interventional radiology procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transvaginal occlusion of the uterine arteries is also under investigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\", section on 'Uterine artery occlusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432924\">",
"    <span class=\"h2\">",
"     Myolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myolysis refers to laparoscopic thermal coagulation or cryoablation (cryomyolysis) of leiomyoma tissue to reduce myoma size (by approximately 50 percent) by means of myoma destruction and interference with local vascular supply [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Laparoscopic myolysis has been performed using a number of energy sources, including bipolar electrosurgery, Nd:YAG laser, and cryogenic probes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myolysis is easier to master than laparoscopic myomectomy, since it does not require laparoscopic suturing. However, localized tissue destruction without repair may increase the chance of subsequent adhesion formation (in one study, dense adhesions were found in 6 of 15 women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/60\">",
"     60",
"    </a>",
"    ]) or uterine rupture during subsequent pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most experts do not recommend myolysis for women who wish future fertility. Candidates for myolysis are further limited to women with fewer than four leiomyomas with the largest leiomyoma less than 10 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/62\">",
"     62",
"    </a>",
"    ]. Few surgeons have experience with laparoscopic myolysis, and we prefer laparoscopic myomectomy.",
"   </p>",
"   <p>",
"    In women with menorrhagia, myolysis combined with endometrial ablation may be more effective therapy than either procedure alone, but this is investigational. An observational study comparing ablation alone versus with the combined procedure found that the risks of a second surgery were 38 and 13 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/48/8970/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"       \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7666324\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laparoscopic myomectomy is the laparoscopic removal of leiomyomas from the uterus, leaving the uterus in place. (See",
"      <a class=\"local\" href=\"#H7666316\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common indications for laparoscopic myomectomy are abnormal uterine bleeding or bulk-related symptoms (eg,",
"      <span class=\"nowrap\">",
"       pelvic/abdominal",
"      </span>",
"      pain or pressure). Indications for which the benefit of laparoscopic (or abdominal) myomectomy is unproven include: evaluation of pelvic malignancy (eg, ovarian or uterine cancer), infertility, and prevention of obstetric complications. (See",
"      <a class=\"local\" href=\"#H2968903\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2968910\">",
"       'Unproven indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determining whether a woman is a candidate for laparoscopic myomectomy depends upon the location, size, and number of leiomyomas. Pedunculated subserosal fibroids are the easiest to remove, but myomas in other locations can also be excised laparoscopically. Performing laparoscopic myomectomy in women with large or numerous myomas is likely to be time consuming, particularly since morcellation is usually required. (See",
"      <a class=\"local\" href=\"#H3730094\">",
"       'Candidates for laparoscopic myomectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest laparoscopic rather than abdominal myomectomy for women with leiomyomas for whom laparoscopic removal is technically feasible (by size, number, and location) and who have easy access to a surgeon with advanced laparoscopic skills (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3730101\">",
"       'Laparoscopic versus open myomectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of uterine rupture in a pregnancy subsequent to laparoscopic myomectomy is not well established. To optimize myometrial wound repair, we limit the use of electrosurgical desiccation of bleeding vessels and use a multi-layered closure of myometrium. (See",
"      <a class=\"local\" href=\"#H26570231\">",
"       'Measures to reduce blood loss'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26570330\">",
"       'Closure of uterine defects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3565445\">",
"       'Uterine rupture during pregnancy following myomectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative laparoscopic techniques for treatment of leiomyomas have been investigated. For women with symptomatic leiomyomas:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest laparoscopic myomectomy rather than laparoscopic uterine artery occlusion or myolysis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest uterine artery embolization rather than laparoscopic uterine artery occlusion (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H432882\">",
"       'Alternative laparoscopic techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common complications of laparoscopic myomectomy are hemorrhage, fever, and conversion to laparotomy. Visceral injury and other complications occur rarely. (See",
"      <a class=\"local\" href=\"#H1390846\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following laparoscopic myomectomy, the five-year rate of persistent or new myomas is approximately 53 percent, but the rate of women undergoing reoperation is approximately 7 percent. (See",
"      <a class=\"local\" href=\"#H1881843\">",
"       'Persistent or new myomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Robotic myomectomy may benefit some surgeons who have difficulty with laparoscopic suturing, but there are no data to show meaningful benefit to women over the outcomes achieved with laparoscopic myomectomy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/1\">",
"      Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/2\">",
"      Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/3\">",
"      Serden SP, Brooks PG. Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med 1991; 36:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/4\">",
"      Parker WH, Rodi IA. Patient selection for laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 1994; 2:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/5\">",
"      Sizzi O, Rossetti A, Malzoni M, et al. Italian multicenter study on complications of laparoscopic myomectomy. J Minim Invasive Gynecol 2007; 14:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/6\">",
"      Jin C, Hu Y, Chen XC, et al. Laparoscopic versus open myomectomy--a meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 2009; 145:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/7\">",
"      Bulletti C, Polli V, Negrini V, et al. Adhesion formation after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 1996; 3:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/8\">",
"      Advincula AP, Xu X, Goudeau S 4th, Ransom SB. Robot-assisted laparoscopic myomectomy versus abdominal myomectomy: a comparison of short-term surgical outcomes and immediate costs. J Minim Invasive Gynecol 2007; 14:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/9\">",
"      Barakat EE, Bedaiwy MA, Zimberg S, et al. Robotic-assisted, laparoscopic, and abdominal myomectomy: a comparison of surgical outcomes. Obstet Gynecol 2011; 117:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/10\">",
"      Ascher-Walsh CJ, Capes TL. Robot-assisted laparoscopic myomectomy is an improvement over laparotomy in women with a limited number of myomas. J Minim Invasive Gynecol 2010; 17:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/11\">",
"      Advincula AP, Song A, Burke W, Reynolds RK. Preliminary experience with robot-assisted laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 2004; 11:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/12\">",
"      Nezhat C, Lavie O, Hsu S, et al. Robotic-assisted laparoscopic myomectomy compared with standard laparoscopic myomectomy--a retrospective matched control study. Fertil Steril 2009; 91:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/13\">",
"      Hurst BS, Matthews ML, Marshburn PB. Laparoscopic myomectomy for symptomatic uterine myomas. Fertil Steril 2005; 83:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/14\">",
"      Bedient CE, Magrina JF, Noble BN, Kho RM. Comparison of robotic and laparoscopic myomectomy. Am J Obstet Gynecol 2009; 201:566.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/15\">",
"      George A, Eisenstein D, Wegienka G. Analysis of the impact of body mass index on the surgical outcomes after robot-assisted laparoscopic myomectomy. J Minim Invasive Gynecol 2009; 16:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/16\">",
"      Greenberg JA, Einarsson JI. The use of bidirectional barbed suture in laparoscopic myomectomy and total laparoscopic hysterectomy. J Minim Invasive Gynecol 2008; 15:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/17\">",
"      Lee JH, Choi JS, Jeon SW, et al. Single-port laparoscopic myomectomy using transumbilical GelPort access. Eur J Obstet Gynecol Reprod Biol 2010; 153:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/18\">",
"      Kim YW, Park BJ, Ro DY, Kim TE. Single-port laparoscopic myomectomy using a new single-port transumbilical morcellation system: initial clinical study. J Minim Invasive Gynecol 2010; 17:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/19\">",
"      Yoshiki N, Okawa T, Kubota T. Single-incision laparoscopic myomectomy with intracorporeal suturing. Fertil Steril 2011; 95:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/20\">",
"      Einarsson JI. Single-incision laparoscopic myomectomy. J Minim Invasive Gynecol 2010; 17:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/21\">",
"      Dueholm M, Lundorf E, Hansen ES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2002; 186:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/22\">",
"      ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009; 113:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/23\">",
"      Kocak I, Ust&uuml;n C, Emre B, Uzel A. Antibiotics prophylaxis in laparoscopy. Ceska Gynekol 2005; 70:269.",
"     </a>",
"    </li>",
"    <li>",
"     Vokach-Brodsky, L. Anesthesia. In: Nezhat's Operative Gynecologic Laparoscopy and Hysteroscopy, Nezhat, C, Nezhat, FR, Nezhat, C, eds. (Eds), Cambridge University Press, New York 2008. p.37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/25\">",
"      Agarwala N, Liu CY. Safe entry techniques during laparoscopy: left upper quadrant entry using the ninth intercostal space--a review of 918 procedures. J Minim Invasive Gynecol 2005; 12:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/26\">",
"      Koh C, Janik G. Laparoscopic myomectomy: the current status. Curr Opin Obstet Gynecol 2003; 15:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/27\">",
"      Litta P, Fantinato S, Calonaci F, et al. A randomized controlled study comparing harmonic versus electrosurgery in laparoscopic myomectomy. Fertil Steril 2010; 94:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/28\">",
"      Zhao F, Jiao Y, Guo Z, et al. Evaluation of loop ligation of larger myoma pseudocapsule combined with vasopressin on laparoscopic myomectomy. Fertil Steril 2011; 95:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/29\">",
"      Dubuisson JB, Fauconnier A, Deffarges JV, et al. Pregnancy outcome and deliveries following laparoscopic myomectomy. Hum Reprod 2000; 15:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/30\">",
"      Nezhat C. The \"cons\" of laparoscopic myomectomy in women who may reproduce in the future. Int J Fertil Menopausal Stud 1996; 41:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/31\">",
"      Hockstein S. Spontaneous uterine rupture in the early third trimester after laparoscopically assisted myomectomy. A case report. J Reprod Med 2000; 45:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/32\">",
"      Paul GP, Naik SA, Madhu KN, Thomas T. Complications of laparoscopic myomectomy: A single surgeon's series of 1001 cases. Aust N Z J Obstet Gynaecol 2010; 50:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/33\">",
"      Sinha R, Hegde A, Mahajan C, et al. Laparoscopic myomectomy: do size, number, and location of the myomas form limiting factors for laparoscopic myomectomy? J Minim Invasive Gynecol 2008; 15:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/34\">",
"      Landi S, Zaccoletti R, Ferrari L, Minelli L. Laparoscopic myomectomy: technique, complications, and ultrasound scan evaluations. J Am Assoc Gynecol Laparosc 2001; 8:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/35\">",
"      Malzoni M, Rotond M, Perone C, et al. Fertility after laparoscopic myomectomy of large uterine myomas: operative technique and preliminary results. Eur J Gynaecol Oncol 2003; 24:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/36\">",
"      Andrei B, Crovini G, Rosi A. Uterine myomas: pelviscopic treatment. Clin Exp Obstet Gynecol 1999; 26:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/37\">",
"      Dubuisson JB, Fauconnier A, Chapron C, et al. Second look after laparoscopic myomectomy. Hum Reprod 1998; 13:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/38\">",
"      Mais V, Ajossa S, Piras B, et al. Prevention of de-novo adhesion formation after laparoscopic myomectomy: a randomized trial to evaluate the effectiveness of an oxidized regenerated cellulose absorbable barrier. Hum Reprod 1995; 10:3133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/39\">",
"      Hasson HM, Rotman C, Rana N, et al. Laparoscopic myomectomy. Obstet Gynecol 1992; 80:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/40\">",
"      Broder MS, Goodwin S, Chen G, et al. Comparison of long-term outcomes of myomectomy and uterine artery embolization. Obstet Gynecol 2002; 100:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/41\">",
"      Yoo EH, Lee PI, Huh CY, et al. Predictors of leiomyoma recurrence after laparoscopic myomectomy. J Minim Invasive Gynecol 2007; 14:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/42\">",
"      Nezhat FR, Roemisch M, Nezhat CH, et al. Recurrence rate after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 1998; 5:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/43\">",
"      Minig L, Trimble EL, Sarsotti C, et al. Building the evidence base for postoperative and postpartum advice. Obstet Gynecol 2009; 114:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/44\">",
"      Tsuji S, Takahashi K, Imaoka I, et al. MRI evaluation of the uterine structure after myomectomy. Gynecol Obstet Invest 2006; 61:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/45\">",
"      Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004; 104:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/46\">",
"      Parker WH, Einarsson J, Istre O, Dubuisson JB. Risk factors for uterine rupture after laparoscopic myomectomy. J Minim Invasive Gynecol 2010; 17:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/47\">",
"      Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/48\">",
"      Hald K, Langebrekke A, Kl&oslash;w NE, et al. Laparoscopic occlusion of uterine vessels for the treatment of symptomatic fibroids: Initial experience and comparison to uterine artery embolization. Am J Obstet Gynecol 2004; 190:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/49\">",
"      Yen YK, Liu WM, Yuan CC, Ng HT. Laparoscopic bipolar coagulation of uterine vessels to treat symptomatic myomas in women with elevated Ca 125. J Am Assoc Gynecol Laparosc 2001; 8:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/50\">",
"      Lichtinger M, Hallson L, Calvo P, Adeboyejo G. Laparoscopic uterine artery occlusion for symptomatic leiomyomas. J Am Assoc Gynecol Laparosc 2002; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/51\">",
"      Hald K, Kl&oslash;w NE, Qvigstad E, Istre O. Laparoscopic occlusion compared with embolization of uterine vessels: a randomized controlled trial. Obstet Gynecol 2007; 109:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/52\">",
"      Wang PH, Liu WM, Fuh JL, et al. Laparoscopic uterine vessel occlusion in the treatment of women with symptomatic uterine myomas with and without adding laparoscopic myomectomy: 4-year results. J Minim Invasive Gynecol 2008; 15:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/53\">",
"      Hald K, Noreng HJ, Istre O, Kl&oslash;w NE. Uterine artery embolization versus laparoscopic occlusion of uterine arteries for leiomyomas: long-term results of a randomized comparative trial. J Vasc Interv Radiol 2009; 20:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/54\">",
"      Chang WC, Chou LY, Chang DY, et al. Simultaneous laparoscopic uterine artery ligation and laparoscopic myomectomy for symptomatic uterine myomas with and without in situ morcellation. Hum Reprod 2011; 26:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/55\">",
"      Goldfarb HA. Laparoscopic coagulation of myoma (myolysis). Obstet Gynecol Clin North Am 1995; 22:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/56\">",
"      Zupi E, Piredda A, Marconi D, et al. Directed laparoscopic cryomyolysis: a possible alternative to myomectomy and/or hysterectomy for symptomatic leiomyomas. Am J Obstet Gynecol 2004; 190:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/57\">",
"      Visvanathan D, Connell R, Hall-Craggs MA, et al. Interstitial laser photocoagulation for uterine myomas. Am J Obstet Gynecol 2002; 187:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/58\">",
"      Nisolle M, Smets M, Malvaux V, et al. Laparoscopic myolysis with the Nd:YAG laser. J Gynecol Surg 1993; 9:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/59\">",
"      Zupi E, Marconi D, Sbracia M, et al. Directed laparoscopic cryomyolysis for symptomatic leiomyomata: one-year follow up. J Minim Invasive Gynecol 2005; 12:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/60\">",
"      Donnez J, Squifflet J, Polet R, Nisolle M. Laparoscopic myolysis. Hum Reprod Update 2000; 6:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/61\">",
"      Arcangeli S, Pasquarette MM. Gravid uterine rupture after myolysis. Obstet Gynecol 1997; 89:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/62\">",
"      Lefebvre G, Vilos G, Allaire C, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can 2003; 25:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/63\">",
"      Vilos GA, Daly LJ, Tse BM. Pregnancy outcome after laparoscopic electromyolysis. J Am Assoc Gynecol Laparosc 1998; 5:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/48/8970/abstract/64\">",
"      Goldfarb HA. Combining myoma coagulation with endometrial ablation/resection reduces subsequent surgery rates. JSLS 1999; 3:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15780 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-2959C7380A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8970=[""].join("\n");
var outline_f8_48_8970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7666324\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7666316\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2968896\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2968903\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2968910\">",
"      - Unproven indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2968938\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2969212\">",
"      CHOOSING A TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2969220\">",
"      Myomectomy versus other treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7666273\">",
"      Choosing the surgical approach for myomectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3730094\">",
"      - Candidates for laparoscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3730101\">",
"      - Laparoscopic versus open myomectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10497672\">",
"      Alternative laparoscopic techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1198933\">",
"      - Robot-assisted laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10497613\">",
"      - Single port laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26569406\">",
"      PREOPERATIVE EVALUATION AND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26569413\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26569434\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26569841\">",
"      GnRH agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26569855\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26569862\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1748360\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7666064\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26570122\">",
"      Laparoscopic port placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26570231\">",
"      Measures to reduce blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26570315\">",
"      Uterine incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26570323\">",
"      Removal and morcellation of myomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26570330\">",
"      Closure of uterine defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1390846\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1880753\">",
"      Hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1881253\">",
"      Fever and infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1881606\">",
"      Bowel or bladder injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1880877\">",
"      Conversion to laparotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1881385\">",
"      Adhesive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1881709\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1750441\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1881815\">",
"      Relief of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1881843\">",
"      Persistent or new myomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1881992\">",
"      INPATIENT POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1840958\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1882151\">",
"      CONCEPTION AND PREGNANCY AFTER MYOMECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1882187\">",
"      Interval to conception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H433213\">",
"      Fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3565445\">",
"      Uterine rupture during pregnancy following myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H432882\">",
"      ALTERNATIVE LAPAROSCOPIC TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432917\">",
"      Uterine artery occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432924\">",
"      Myolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7666324\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/15780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/15780|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/16/30978\" title=\"figure 1\">",
"      Fibroid anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/32/27143\" title=\"figure 2\">",
"      Submucosal leiomyoma position",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=related_link\">",
"      Abdominal myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=related_link\">",
"      Differentiating uterine leiomyomas (fibroids) from uterine sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12168?source=related_link\">",
"      Gynecologic laparoscopy: Non-umbilical entry sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=related_link\">",
"      Hysteroscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9029?source=related_link\">",
"      Laparoendoscopic single-site (single port) surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41735?source=related_link\">",
"      Overview of the principles of medical consultation and perioperative medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=related_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=related_link\">",
"      Postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=related_link\">",
"      Postoperative ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=related_link\">",
"      Pregnancy in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=related_link\">",
"      Preventing postoperative peritoneal adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=related_link\">",
"      Prolapsed uterine leiomyoma (fibroid)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=related_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=related_link\">",
"      Small bowel obstruction: Causes and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=related_link\">",
"      Techniques to reduce blood loss during abdominal or laparoscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=related_link\">",
"      Treatment of primary dysmenorrhea in adult women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_48_8971="Proportion CV events SCD";
var content_f8_48_8971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proportion of coronary fatalities that are sudden deaths: Framingham study",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Percent as sudden deaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Age 35 to 64",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 65 to 94",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 35 to 94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Men",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8971=[""].join("\n");
var outline_f8_48_8971=null;
var title_f8_48_8972="Calcium and regulation of PTH";
var content_f8_48_8972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    PTH homeostasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 214px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of parathyroid hormone (PTH) on calcium and phosphate metabolism. The net effect is an increase in the plasma calcium concentration with no change or a decrease in the plasma phosphate concentration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8972=[""].join("\n");
var outline_f8_48_8972=null;
var title_f8_48_8973="Hormone levels in HF";
var content_f8_48_8973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Hormone levels in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 223px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plasma levels of norepinephrine, renin activity, and antidiuretic hormone are increased two to eightfold (when compared to normal subjects) in patients with stable heart failure treated with digitalis, but not diuretics or vasodilators.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Francis GS, Goldsmith SR, Levine TB, et al. Ann Intern Med 1984; 101:370.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8973=[""].join("\n");
var outline_f8_48_8973=null;
var title_f8_48_8974="Radial head fracture complex";
var content_f8_48_8974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Displaced and comminuted fracture of the radial head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 224px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These radiographs show a significantly displaced and comminuted fracture of the radial head (Mason Type III).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Slabaugh, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8974=[""].join("\n");
var outline_f8_48_8974=null;
var title_f8_48_8975="Molar tooth sign";
var content_f8_48_8975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molar tooth sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Brain MRI axial image in a patient with Joubert syndrome at the level of the superior cerebellar peduncles showing an abnormally increased depth of the interpeduncular fossa, narrowing of the midbrain tegmentum, and thickening of the superior cerebellar peduncles, all of which contribute to the radiologic feature known as the \"molar tooth sign.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_48_8975=[""].join("\n");
var outline_f8_48_8975=null;
